CONSOLIDATED FINANCIAL STATEMENTS, SUPPLEMENTARY INFORMATION AND REPORTS ON FEDERAL AND STATE AWARD PROGRAMS

CHRISTUS Health Years Ended June 30, 2020 and 2019 With Reports of Independent Auditors

Ernst & Young LLP



Consolidated Financial Statements, Supplementary Information and Reports on Federal and State Award Programs

Years Ended June 30, 2020 and 2019

Contents

Part I – Financial	
Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	
Consolidated Statements of Operations and Changes in Net Assets	5
Consolidated Statements of Cash Flows	7
Notes to Consolidated Financial Statements	9
Supplementary Information	
Report of Independent Auditors on Supplementary Information	74
Community Benefit (Unaudited)	75
Supplementary Information – Federal and State Awards	
Schedule of Compensation Information	76
Schedule of Expenditures of Federal and State Awards	77
Notes to Schedule of Expenditures of Federal and State Awards	80
Part II – Internal Control and Compliance Reports	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of the Financial Statements	
Performed in Accordance With Government Auditing Standards	82
Report of Independent Auditors on Compliance for Each Major Federal and State	
Program and Report on Internal Control Over Compliance Required by the Uniform	
Guidance and State of Texas Uniform Grant Management Standards	84
Schedule of Findings and Questioned Costs	
Section I – Summary of Auditor's Results	
Section II – Financial Statement Findings	
Section III – Federal Award Findings and Questioned Costs	
Section IV – State Award Findings and Questioned Costs	88



Ernst & Young LLP One Victory Park Suite 2000 2323 Victory Avenue Dallas, TX 75219 Tel: +1 214 969 8000 Fax: +1 214 969 8587 ey.com

Report of Independent Auditors

The Board of Directors and Management CHRISTUS Health

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of CHRISTUS Health, which comprise the consolidated balance sheets as of June 30, 2020 and 2019, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of CHRISTUS Health as of June 30, 2020 and 2019, and the results of its consolidated operations and changes in its net assets and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.



Adoption of ASU No. 2016-02, Leases (Topic 842)

As discussed in Note 3 to the consolidated financial statements, CHRISTUS Health changed its method of accounting for leases as a result of the adoption of amendments to the FASB Accounting Standards Codification resulting from Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*, effective July 1, 2019. Our opinion is not modified with respect to this matter.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to September 24, 2020. The accompanying schedule of compensation information as required by the Louisiana Revised Statute 24: 513A(1)(a)(3) and schedule of expenditures of federal and state awards as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and the State of Texas Uniform Grant Management Standards are presented for purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the schedule of compensation information and the schedule of expenditures of federal and state awards are fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated September 24, 2020, on our consideration of CHRISTUS Health's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of CHRISTUS Health's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering CHRISTUS Health's internal control over financial reporting and compliance.

Ernst + Young LLP

September 24, 2020, except for our report on the Schedule of Expenditures of Federal and State awards, for which the date is September 22, 2021.

Consolidated Balance Sheets

	June 30		
	2020	2019	
	(In The	ousands)	
Assets			
Current assets:			
Cash and cash equivalents	\$ 1,271,062	\$ 578,621	
Short-term investments and equity in managed funds	882,313	755,192	
Assets whose use is limited or restricted, required for			
current liabilities	52,685	65,872	
Patient accounts receivable	500,091	534,190	
Notes and other receivables	220,554	208,861	
Inventories	126,453	110,402	
Other current assets	122,150	103,449	
Total current assets	3,175,308	2,356,587	
Assets whose use is limited or restricted, less current portion	783,062	797,632	
Property and equipment, net of accumulated depreciation	2,806,200	2,725,526	
Other assets:			
Investments in unconsolidated organizations	238,682	234,059	
Goodwill and intangible assets, net	163,816	163,233	
Finance lease right-of-use assets, net	74,411	_	
Operating lease right-of-use assets, net	222,509	_	
Beneficial interest in supporting organizations	125,757	107,355	
Other assets, including notes receivable from related party	185,832	232,015	
Total other assets	1,011,007	736,662	
Total assets	\$ 7,775,577	\$ 6,616,407	

3 2005-3516145

	June 30			
		2020		2019
		(In The	ouse	ands)
Liabilities and net assets				
Current liabilities:				
Accounts payable and accrued expenses	\$	631,815	\$	638,215
Accrued employee compensation and benefits		270,907		221,741
Deferred revenue		762,136		31,241
Current portion of long-term debt		49,559		41,116
Current portion of finance lease liabilities		7,179		_
Current portion of operating lease liabilities		48,849		-
Long-term obligations subject to remarketing agreements	_	38,305		
Total current liabilities		1,808,750		932,313
Long-term debt, less current portion		1,488,906		1,607,209
Accrued pension benefits		182,290		153,673
Derivative financial instruments		187,339		126,772
Long-term finance lease liabilities		109,957		_
Long-term operating lease liabilities		190,654		_
Other long-term obligations – including self-funded liabilities,				
less current portion		216,517		250,178
Total liabilities		4,184,413		3,070,145
Net assets:				
Net assets without donor restrictions:				
Attributable to CHRISTUS Health		3,019,768		3,007,092
Attributable to noncontrolling interest		366,027		332,804
Total net assets without donor restriction		3,385,795		3,339,896
Net assets with donor restrictions		205,369		206,366
Total net assets		3,591,164		3,546,262
Total liabilities and net assets	\$	7,775,577	\$	6,616,407

See accompanying notes.

Consolidated Statements of Operations and Changes in Net Assets

	Year Ended June 30 2020 2019		
	(In The	ousands)	
Revenues:			
Net patient service revenue	\$ 5,072,538	\$ 5,047,880	
Premium revenue	300,207	285,338	
Other revenue	355,599	228,126	
Total revenues	5,728,344	5,561,344	
Expenses:			
Employee compensation and benefits	2,597,911	2,510,649	
Services and other	1,742,965	1,687,916	
Supplies	953,555	951,817	
Depreciation and amortization	245,173	230,951	
Interest	59,579	53,230	
Total expenses	5,599,183	5,434,563	
Operating income	129,161	126,781	
Nonoperating investment (loss) gain, net	(14,888)	·	
Other nonoperating gain (loss)	14,425	(6,759)	
Revenues in excess of expenses	128,698	126,445	
Less revenues in excess of expenses attributable to			
noncontrolling interests	36,055	35,923	
Revenues in excess of expenses attributable to			
CHRISTUS Health	92,643	90,522	

Consolidated Statements of Operations and Changes in Net Assets (continued)

	Year Ended June 30			
		2020		2019
		(In Tho	usa	nds)
Net assets without donor restrictions:				
Revenues in excess of expenses attributable to				
CHRISTUS Health	\$	92,643	\$	90,522
Unrealized gain on investments		219		1,008
Change in pension liabilities		(54,717)		(61,183)
Change in noncontrolling interest		33,223		94,682
Cumulative adjustment related to ASC 842 implementation		7,129		_
Net assets released from restrictions for capital and other		(32,598)		13,074
Changes in net assets without donor restrictions		45,899		138,103
Net assets with donor restrictions:				
Net change in beneficial interests		(11,080)		4,734
Contributions		19,151		11,471
Unrealized gain on investments		197		589
Net assets released from restrictions and other		(9,265)		(10,803)
Changes in net assets with donor restrictions		(997)		5,991
Change in net assets		44,902		144,094
Net assets – beginning of fiscal year		3,546,262		3,402,168
Net assets – end of fiscal year	\$			3,546,262

See accompanying notes.

Consolidated Statements of Cash Flows

		Year Ended June 30 2020 2019		
		(In Thous	sands)	
Operating activities	_			
Change in net assets	\$	44,902 S	144,094	
Adjustments to reconcile change in net assets to net cash				
provided by operating activities:				
Change in beneficial interests		(18,402)	2,053	
Change in pension liabilities recognized in net assets		54,717	61,183	
Contributions of net assets with donor restrictions		(19,151)	(11,471)	
Distributions to, acquisitions, and sale of noncontrolling interest, net		5,858	(52,609)	
Distributions from investments in unconsolidated organizations		10,938	6,771	
Equity in (earnings) losses of unconsolidated organizations		(4,171)	3,364	
Unrealized investment gain		(13,005)	(16,188)	
Depreciation and amortization		245,173	230,951	
Amortization of premiums, discounts, and deferred financing costs		1,015	1,055	
Change in derivative fair value		60,567	40,200	
Loss on extinguishment of debt		-	20,348	
Gain on disposal of property and equipment		(2,314)	(1,391)	
Foreign currency translation adjustment		30,013	(4,709)	
Changes in operating assets and liabilities, net of acquisitions:		50,015	(4,702)	
Decrease (increase) in net patient accounts receivable		34,099	(8,874)	
(Increase) decrease in investments and assets whose use is limited or		34,022	(0,074)	
restricted		(172.570)	42,966	
Increase in notes and other receivables		(172,570)	(7,121)	
Increase in notes and other receivables Increase in other current assets and inventories		(11,654)		
		(31,300)	(17,014)	
Increase (decrease) in accounts payable, accrued expenses, and accrued		45 577	(20.057)	
employee compensation and benefits		45,566	(29,957)	
Increase in deferred revenue		730,895	_	
Increase (decrease) in other long-term liabilities	,	8,183	(4,362)	
Net cash provided by operating activities		999,359	399,289	
Investing activities				
Investing activities Purchases of property and equipment		(450 510)	(262 172)	
		(452,510)	(363,173)	
Proceeds from sale or disposal of property and equipment		2,739	(29, (52)	
Purchases of or contributions to investments in unconsolidated organizations Decrease (increase) in other-than-trading investments and assets limited as to		(10,777)	(38,652)	
		40.00=	(77.095)	
Use Degrees (increase) in other resets		49,085	(77,985)	
Decrease (increase) in other assets		48,706	(44,315)	
Acquisitions of healthcare entities, net of cash acquired		(33,349)		
Net cash used in investing activities		(396,106)	(524,060)	

Consolidated Statements of Cash Flows (continued)

	Year Ended June 30 2020 2019			
	***************************************	(In The	ousa	nds)
Financing activities Contributions of net assets with donor restrictions	\$	19,151	S	11,471
Purchases and sales of noncontrolling interests		2,182		33,229
Proceeds from issuance of new debt, net of issuance costs		92,129		943,572
Payments on long-term debt, including deposits into escrow for defeasance		(47,011)		(615,656)
Payments on financing leases		(6,349)		_
Distributions to noncontrolling interest holders		(8,040)		(8,044)
Net cash provided by financing activities		52,062		364,572
Net increase in cash, cash equivalents, and restricted cash		655,315		239,801
Cash, cash equivalents, and restricted cash – beginning of fiscal year		790,985		551,184
Cash, cash equivalents, and restricted cash – end of fiscal year	\$	1,446,300	S	790,985
Reconciliation of cash, cash equivalents, and restricted cash	_		_	
Cash and cash equivalents at beginning of fiscal year	\$	578,621	S	398,086
Restricted cash included in assets whose use is limited or restricted at				***
beginning of fiscal year		212,364		153,098
Cash, cash equivalents, and restricted cash at beginning of fiscal year	\$	790,985	S	551,184
Cash and cash equivalents at end of fiscal year	\$	1,271,062	s	578,621
Restricted cash included in assets whose use is limited or restricted at end of fiscal year		175,238		212,364
Cash, cash equivalents, and restricted cash at end of fiscal year	\$	1,446,300	S	790,985
Noncash investing and financing transactions	_		_	
Capital lease and debt obligations incurred for property and equipment	\$	_	S	772
Notes issued in exchange for noncontrolling interests in consolidated				
organizations	\$	_	S	27,424
-				
Supplemental disclosure of cash flow information			_	
Cash paid during the year for interest (net of amount capitalized)	\$	55,737	S	42,150

See accompanying notes.

Notes to Consolidated Financial Statements

June 30, 2020

1. Mission, Vision, and Organization of CHRISTUS Health

CHRISTUS Health was incorporated as a Texas nonprofit corporation on December 15, 1998. CHRISTUS is sponsored by the Congregation of the Sisters of Charity of the Incarnate Word of Houston, Texas; the Congregation of the Sisters of Charity of the Incarnate Word of San Antonio, Texas; and the Congregation of the Sisters of the Holy Family of Nazareth. CHRISTUS Health together with each affiliated entity for which CHRISTUS Health holds, directly or indirectly, at least a majority membership, ownership or other controlling interest are collectively referred to in these consolidated financial statements as CHRISTUS or the System.

The mission of CHRISTUS is to extend the healing ministry of Jesus Christ. The Gospel values underlying the mission statement challenge CHRISTUS to make choices that respond to the economically disadvantaged and the underserved with healthcare needs. The growth and development of CHRISTUS are determined by the healthcare needs of the communities that CHRISTUS serves, its available resources, and the interrelationship of those serving and those being served. Responsible stewardship mandates that CHRISTUS searches out new, effective means to deliver quality healthcare and to promote wholeness in the human person.

The vision of CHRISTUS is to be a leader, a partner, and an advocate in the creation of innovative health and wellness solutions that improve the lives of individuals and communities so that all may experience God's healing presence and love.

The consolidated financial statements reflect the results of operations of CHRISTUS Health and its affiliated market-based healthcare provider organizations and other related entities and functions (all of which are, or further the work of, CHRISTUS ministries). These include but are not limited to hospitals, physician groups, ambulatory surgery centers, diagnostic imaging companies, urgent care centers, health plans, integrated community health networks, foundations, professional office buildings, management services organizations, a collection agency, self-insurance trusts, and an offshore captive insurance company.

CHRISTUS entities control or own, directly or indirectly, or manage various nonprofit and forprofit corporations and other organizations that currently operate domestically in the states of Texas, Louisiana, and New Mexico, and internationally in Grand Cayman, Mexico, Chile, and Colombia.

Notes to Consolidated Financial Statements (continued)

1. Mission, Vision, and Organization of CHRISTUS Health (continued)

CHRISTUS Health and certain affiliated nonprofit corporations are generally exempt from federal income taxes under Section 501(a) of the Internal Revenue Code, as organizations described in Section 501(c)(3).

2. Community Health

In accordance with its mission and philosophy, the System commits significant resources to improving the health of the communities it serves. In support of its mission, the System provides programs and services for entire communities, with a special consideration for those who are poor and underserved.

CHRISTUS and various hospital participants have elected to provide healthcare services to the indigent population both directly to patients as charity services and by providing financial support to one another for certain community benefit efforts provided throughout the year with the goal being to reach a previously discussed equitable distribution of the cost of care to the low-income and needy populations in the communities they service.

Programs and Services for the Poor and Underserved

These programs and services represent the financial commitment to serve those who have inadequate resources and/or are uninsured or underinsured. Services are offered with the conviction that healthcare is a basic human right and all deserve access. The categories included as programs and services for the poor and the underserved are as follows:

Charity Care – In accordance with the Catholic Health Association (CHA) guidelines, charity care represents the unpaid costs of free or discounted health services provided to persons who cannot afford to pay and who meet the organization's criteria for financial assistance. Traditional charity care is defined by the state of Texas as the unreimbursed costs of providing, funding, or otherwise financially supporting the healthcare services provided to a person with income at or below 200% of the federal poverty level. Charity care services provided to these patients are not reported as revenue in the consolidated statements of operations and changes in net assets, as there is no expectation of payment. The amount of traditional charity care provided, determined on the basis of cost, estimated using the applicable cost to charge ratios of the hospital participants was \$276,137,000 and \$290,531,000 for the fiscal years ended June 30, 2020 and 2019, respectively.

Notes to Consolidated Financial Statements (continued)

2. Community Health (continued)

Unpaid Costs of Medicaid and Other Public Programs for the Indigent – This category represents the cost of providing services to beneficiaries of public programs, including state Medicaid and indigent care programs, in excess of any payments received from all sources.

Community Services for the Poor and Underserved – This category represents the unpaid cost of services provided for which a patient is not billed or for which a fee has been assessed that recovers only a portion of the cost of the rendered service. This category includes services to those in need through community health programs. The programs cover a broad spectrum of services, including community health centers, immunizations for children and seniors, Meals on Wheels, transportation services, home repair projects, and a variety of other social services. These programs may also seek justice for the vulnerable and work to bring about changes in political and economic systems.

Community Services Provided for the Broader Community – This category represents the unpaid cost of services provided for the benefit of the entire community. The majority of these expenditures are for graduate medical education programs, either through CHRISTUS-sponsored or affiliated programs. Other benefits for the broader community include health promotion and wellness programs, health screenings, newsletters, and radio or television programs intended for health education. These programs are not intended to be financially self-supporting.

Education and Research – This category represents the direct costs associated with medical education and other health professional educational programs in excess of governmental payments.

Other Community Services – This category represents leadership activities, community planning, and advocacy.

3. Summary of Significant Accounting Policies

Basis of Consolidation

The consolidated financial statements include the accounts of all entities of the System (see Note 1). All significant intercompany transactions and accounts have been eliminated in consolidation.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Use of Estimates

The preparation of the accompanying consolidated financial statements in conformity with United States generally accepted accounting principles (U.S. GAAP) requires management of the System to make assumptions, estimates, and judgments that affect the amounts reported in the consolidated financial statements, including the notes thereto, and related disclosures of commitments and contingencies, if any. The System considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: recognition of net patient service revenues, which include price concessions; estimates for reimbursement under the upper payment limit, disproportionate share, and Medicaid 1115 waiver programs; recognition of government relief funding; reserves for losses and expenses related to healthcare professional and general liabilities; accruals for claims incurred but not yet reported and for risk-sharing liabilities related to the System's health plan; determination of fair values of certain financial instruments; determination of fair value of certain goodwill and long-lived assets, including assets acquired; determination of lease right-of-use assets and liabilities; and risks and assumptions for measurement of pension and retiree medical liabilities. Management relies on historical experience and on other assumptions believed to be reasonable under the circumstances in making its judgments and estimates. Actual results could differ materially from these estimates.

Cash Equivalents and Investments

Cash equivalents include short-term, highly liquid investments with original maturities of three months or less.

The System's investment portfolio is classified as trading, with unrealized gains and losses included in revenues in excess of expenses. Certain investments held by the System's foundations are classified as other than trading, with unrealized gains and losses included in changes in net assets. Investments in equity securities and funds with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheets. Investments also include equity investments in managed funds structured as limited liability corporations or partnerships. Equity investments in managed funds are accounted for under the fair value method if held within the System's foundations or captive insurer, or under the equity method of accounting if held by another System entity. Investment income or loss (including equity investment earnings (losses) on equity investments in managed funds; realized and

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

unrealized gains and losses, computed on the average-cost basis of the security at the time of sale; and interest and dividends) is included in revenues in excess of expenses unless the income or loss is restricted by donor or law.

Investment income earned on assets held by trustees under bond indenture agreements, assets held by foundations, assets deposited in trust funds for self-insurance purposes, holdings in healthcare-related investment funds, and funds held by insurance subsidiaries in accordance with industry practices are included in other revenue in the consolidated statements of operations and changes in net assets.

Derivative Financial Instruments

The System utilizes interest rate swaps to mitigate interest rate exposures. Changes in the fair value of the System's interest rate swaps are recorded as a component of nonoperating investment (loss) gain in the accompanying consolidated statements of operations and changes in net assets. The expense or income representing the net of the payments made and received under the swap agreements is also recorded as a component of nonoperating investment (loss) gain.

Inventories

The System values inventories, which consist principally of medical supplies and pharmaceuticals, at the lower of cost (first-in, first-out or weighted average cost valuation method) or net realizable value.

Property and Equipment

Property and equipment acquisitions are recorded at historical cost or, if donated, impaired, or acquired in a business transaction, at fair value at the time of donation, impairment, or acquisition. Expenditures that materially increase values, change capacities, or extend useful lives are capitalized. Routine maintenance, repairs, and minor equipment replacement costs are charged against operations.

Depreciation is calculated and recorded over the estimated useful life of each class of depreciable assets using the straight-line method. The *American Hospital Association – Estimated Useful Lives of Depreciable Hospital Assets* is used as a general guide in establishing depreciable lives. Amortization of capital leases and impairment losses related to long-lived assets are included in depreciation expense.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Internal-Use Software

Costs to develop internal-use software and internal-use software obtained through a hosting arrangement are capitalized during the application development phase accordance with Accounting Standards Codification (ASC) 350-40. At June 30, 2020 and 2019, the System had capitalized costs related to internal-use software obtained through a hosting arrangement of \$33,019,000 and \$16,292,000, respectively, included in other assets in the consolidated balance sheets.

Asset Impairment

The System periodically evaluates the carrying value of its operating long-lived assets and assets held for sale for impairment when indicators of impairment are identified. These evaluations are primarily based on the estimated recoverability of the assets' carrying value. Impairment writedowns are recognized as a reduction in operating income for the operating long-lived assets and as a reduction in nonoperating gain for the assets held for sale at the time the impairment is identified. There were no material impairment losses recognized in fiscal years 2020 or 2019.

Investments in Unconsolidated Organizations

The System has investments in certain organizations for which it does not have a majority ownership interest or control, and therefore, these organizations are not consolidated. Generally, these investments are recorded using the equity method of accounting for those organizations in which the System owns greater than 20% and has significant influence over the organization. The System measures its equity investments in organizations in which the System owns 20% or less at cost less impairment, if any, because these investments do not have a readily determinable fair value (see additional discussion in Note 9). Equity income (losses) of \$3,701,000 and \$(3,364,000) for the fiscal years ended June 30, 2020 and 2019, respectively, are reflected in other revenue in the consolidated statements of operations. Equity losses in 2019 include an impairment charge of \$16,885,000 related to the investment in the System's Colombian operations.

Noncontrolling Interests in Consolidated Subsidiaries

The System attributed revenues in excess of expenses of \$36,055,000 and \$35,923,000 for the fiscal years ended June 30, 2020 and 2019, respectively, to the noncontrolling interests based on the contractual terms of joint ventures and the ownership percentage of the noncontrolling interests

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

in certain of the consolidated subsidiaries. Noncontrolling interests are reflected as a component of net assets without donor restrictions in the consolidated balance sheets, net of distributions.

Goodwill and Intangible Assets

Goodwill and intangible assets recorded in connection with acquisitions completed by the System are accounted for under ASC 350, *Intangibles – Goodwill and Other*. The System records goodwill as the excess of the purchase price over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed. Indefinite-lived intangible assets consist entirely of a trade name asset recorded in connection with the Trinity Mother Frances Health System acquisition in fiscal year 2016. Finite-lived intangible assets consist primarily of noncompete assets generated from business combinations and minimum revenue guarantees offered to various non-employed physicians throughout the System.

The changes in the carrying amounts of goodwill and intangible assets as of June 30 are as follows (in thousands):

	 Goodwill	 definite- ved Asset	Fi	nite-Lived Assets
Balance at July 1, 2018	\$ 108,810	\$ 46,000	\$	8,465
Assets acquired	1,396	_		4,798
Amortization	_	_		(4,441)
Currency translation and other				•
adjustments	(1,795)	_		_
Balance at June 30, 2019	 108,411	46,000		8,822
Assets acquired	_	_		7,327
Amortization	_	_		(5,316)
Currency translation and other				
adjustments	(747)	_		(681)
Balance at June 30, 2020	\$ 107,664	\$ 46,000	\$	10,152

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Goodwill is tested at least annually for impairment at the reporting unit level on April 1 of each year. Impairment is the condition that exists when the carrying amount of goodwill exceeds its implied fair value. Additional impairment assessments may be performed on an interim basis if the System encounters events or changes in circumstances that would indicate that it is more likely than not that the carrying value has been impaired. The System has determined that its reporting units are the various geographically located affiliates.

For goodwill impairment tests, the System may elect to perform a qualitative assessment of each reporting unit to determine whether facts and circumstances support a determination that the reporting unit's fair value is greater than its carrying value. A quantitative assessment is performed for reporting units if the qualitative analysis is not conclusive or if impairment is indicated. If the System performs a quantitative assessment, the fair values of the reporting units are determined and compared with the aggregate carrying values.

If required, the System follows a two-step, fair-value-based process using a discounted cash flow income method, a guideline public company method, and a mergers and acquisitions method to determine whether an impairment of goodwill exists. This analysis requires judgments and estimates about the weighted average cost of capital, risk factors, and forecasted operating margins. The first step compares the fair value of the reporting unit with its carrying amount, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the second step is performed. The second step requires an allocation of fair value to the individual assets and liabilities of the reporting unit to determine the implied fair value of goodwill. If the implied fair value of goodwill is less than the carrying amount, an impairment loss is recorded as a reduction to goodwill and a charge to impairment expense. Judgments and assumptions are inherent in the System's estimates used to determine the fair value of its reporting units and are consistent with what the System believes would be utilized by the primary market participant. The use of alternative judgments and assumptions could result in the recognition of different impairment charges in the System's consolidated financial statements.

As a result of the qualitative assessments for both the fiscal years ended June 30, 2020 and 2019, no impairment losses were recorded.

Indefinite-lived intangible assets are also tested annually for impairment on April 1 of each year, by comparing the fair value of the asset with its carrying amount. The System also considers facts and circumstances surrounding the asset on an annual basis to determine whether an indefinite life continues to be appropriate. For indefinite-lived intangible asset impairment tests, the System also

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

may elect to perform a qualitative assessment to determine whether facts and circumstances support a conclusion that it is more likely than not that the asset is not impaired. If the qualitative analysis is not conclusive, or if the System elects to proceed directly with quantitative testing, the fair values of the intangible assets are determined and compared with their carrying amounts. As a result of the qualitative assessments for both fiscal years ended June 30, 2020 and 2019, no impairment losses on indefinite-lived intangible assets were recorded.

Finite-lived intangible assets are tested for impairment whenever indicators of impairment are identified. An impairment loss is recognized if the intangible asset is not recoverable and its carrying amount exceeds its fair value. No impairment losses on finite-lived intangible assets were recognized in fiscal years 2020 or 2019.

Leases

The System determines whether an arrangement is a lease at inception of the contract and performs an analysis to determine whether the lease is an operating lease or a financing lease. Right-of-use assets represent the System's right to use the underlying assets for the lease term and lease liabilities represent the System's obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The System uses its estimated incremental borrowing rate in determining the present value of lease payments to the extent that the rate inherent in the lease is unknown. The incremental borrowing rate is calculated on a quarterly basis by a third party that estimates the rate of interest the System would have to pay over a term similar to the lease term. The System does not record leases with an initial term of 12 months or less in its consolidated balance sheet.

Deferred Financing Costs

Deferred financing costs, net of accumulated amortization, included as a reduction of long-term debt at June 30, 2020 and 2019, are \$9,194,000 and \$10,209,000, respectively, which are being amortized using the effective interest method over the terms of the indebtedness to which they relate. Amortization expense recognized for fiscal years 2020 and 2019 was \$1,015,000 and \$1,055,000, respectively.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Net Assets With Donor Restrictions

Net assets with donor restrictions reflect the portion of the System's net assets whose use is subject to donor imposed restrictions. Donor imposed restrictions may be temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. These include the System's beneficial interest in the net assets of affiliated and financially interrelated organizations, whose use has been limited by grant agreements and donors to a specific time period or purpose. Other donor imposed restrictions are perpetual in nature, where the assets have been restricted by donors to be maintained by the System in perpetuity.

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received or the condition has been met. The gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations and changes in net assets as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as other revenue in the accompanying consolidated financial statements.

Patient Accounts Receivable, Estimated Payables to Third-Party Payors, and Patient Service Revenue

The System has agreements with third-party payors that provide for payments to the System at amounts different from established rates. Patient accounts receivable and patient service revenue are reported at amounts that reflect the consideration to which CHRISTUS expects to be entitled for providing patient care. Estimated retroactive adjustments under reimbursement agreements with third-party payors are included in patient service revenue and estimated third-party payor settlements. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods, as final settlements are determined.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Premium Revenue and Associated Costs

Premium revenue largely represents revenues derived under capitated arrangements with third parties. In return for these premiums, CHRISTUS is responsible for providing essentially all healthcare services to enrolled participants. The System contracts with the Department of Defense (DOD) to treat TRICARE patients through a US Family Health Plan. Premium revenue recognized under the contract with the DOD was 42.3% and 45.9% of total premium revenue at June 30, 2020 and 2019, respectively.

Premium revenues are also generated by the System's health maintenance organization, CHIP and STAR programs, Medicare Advantage plans, and for individual coverage on federal and state-based health exchanges. Premium revenue for individual coverage on the federal and state-based exchanges, Medicare Advantage, and the CHIP and STAR programs was 57.7% and 54.1% of total premium revenue for the fiscal years ended June 30, 2020 and 2019, respectively. The exchanges revenues are subject to risk-sharing provisions as outlined in federal regulations. Additionally, a significant portion of these premiums is subsidized through the federal government's advance premium tax credit provisions. The purpose of the risk-sharing provisions is to transfer funds from health plans with lower risk to health plans with higher risk within the same state. Risk adjustment assessments and distributions are computed based on a health plan's risk score vs. the overall market risk score. Included in net premium revenues for individual coverage on federal and state-based health exchanges are adjustments for risk-sharing assessments of \$16,593,000 and \$22,661,000 as of June 30, 2020 and 2019, respectively. Ultimate settlement could differ significantly from this estimate.

Costs for providing services through these contracts were \$224,058,000 and \$214,401,000 for the fiscal years ended June 30, 2020 and 2019, respectively, and are included as operating expenses in the accompanying consolidated financial statements. At June 30, 2020 and 2019, the System has accrued expenses for incurred but not reported claims based upon actuarial evaluations of claims experience. These estimates are continually reviewed and adjusted as necessary as experience develops or as new information becomes known; such adjustments are included in current operations. The System maintains stop-loss insurance coverage to limit exposure for certain catastrophic claims.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Other Revenue

Other revenue is derived from services other than providing healthcare services or coverage to patients, residents, or enrollees. This revenue typically includes investment income from all funds held by foundations, bond trustees, malpractice funds, or other miscellaneous investment activities; fees for providing management services under the terms of management agreements with certain of the System's joint ventures and related-party joint venture partners; rental of healthcare facility space; sales of medical and pharmaceutical supplies to employees, physicians, and others; proceeds from sales of cafeteria meals and guest trays to employees, medical staff, and visitors; and proceeds from sales at gift shops and other retail activities or other service facilities operated by the healthcare organization. For the year ended June 30, 2020, other revenue also includes amounts received under the Coronavirus Aid, Relief, and Economic Security (CARES) Act (see Note 4 and Note 20).

Income Taxes

The authoritative guidance in ASC 740, *Income Taxes*, creates a single model to address uncertainty in tax positions and clarifies the accounting for income taxes by prescribing the minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. Under the requirements of this guidance, tax-exempt organizations could be required to record an obligation as the result of a tax position they have historically taken on various tax exposure items. CHRISTUS has interests in various taxable entities, including investments in Mexico and Chile. These interests may give rise to U.S. and international tax exposures. CHRISTUS intends to utilize foreign earnings in foreign operations for an indefinite period of time in order to continue investing all earnings into the continued maintenance and expansion of these operations abroad as part of the System's mission. If these amounts were distributed to the United States, in the form of dividends or otherwise, the System could be subject to additional U.S. income taxes. Determination of the amount of unrecognized deferred income tax liabilities on these earnings is not practicable because such liability, if any, depends on circumstances existing if and when remittance occurs. There are no material unrecorded tax liabilities as of June 30, 2020 or 2019.

At June 30, 2020 and 2019, CHRISTUS has operating loss carryforwards of \$342,806,000 and \$372,537,000, which result in deferred tax assets of \$71,989,000 and \$79,431,000, respectively. CHRISTUS has provided a valuation allowance of the same amount, as it is more likely than not that the deferred tax assets will not be realized.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. Management does not expect a material tax impact on CHRISTUS' financial statements from the provisions of the CARES Act.

Business Combinations

CHRISTUS accounts for all transactions that represent business combinations in which it obtains control of the acquired entity using the acquisition method of accounting, where the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquired entity are recognized and measured at their fair values on the date the System obtains control of the acquiree.

Such fair values that are not finalized for reporting periods following the acquisition date are estimated and recorded as provisional amounts. Adjustments to these provisional amounts during the measurement period (defined as the date through which all information required to identify and measure the consideration transferred, the assets acquired, the liabilities assumed, and any noncontrolling interests has been obtained, limited to one year from the acquisition date) are recorded in the period in which the final amounts are determined. Goodwill is determined as the excess of the purchase price over the fair value of identifiable tangible and intangible assets acquired and liabilities assumed. An inherent contribution is recorded if the fair values of identifiable assets and liabilities acquired exceed the consideration conveyed.

Performance Indicator

The performance indicator is revenues in excess of expenses, which includes all changes in net assets without donor restrictions other than changes in the pension liability funded status, changes in noncontrolling interests, net assets released from restrictions for property acquisitions, unrealized gains and losses on certain investments held by the System's foundations and insurance captive, cumulative effect of changes in accounting principles, discontinued operations, contributions of property and equipment, and other changes not required to be included within the performance indicator under U.S. GAAP.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Operating and Nonoperating Activities

CHRISTUS' primary mission is to meet the healthcare needs in its market areas through a broad range of general and specialized healthcare services, including inpatient acute care, outpatient services, physician services, and other healthcare services. Activities directly associated with furthering this purpose are considered to be operating activities. Earnings from the investment activities of the offshore captive, community foundations, and holdings in healthcare-specific investment funds are also classified as operating activities as such earnings support the operations of those organizations. Other activities that result in gains or losses peripheral to CHRISTUS' primary mission are considered to be nonoperating. Nonoperating activities include all other investment earnings, gains or losses from bond defeasance, and net interest cost and changes in fair value of interest rate swaps.

New Accounting Pronouncements

Effective July 1, 2019, the System adopted the Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-02, enacting ASC 842, Leases, using the modified retrospective transition approach as of the period of adoption for leases that existed on that date. Prior period results continue to be presented under the accounting guidance previously in effect for the period. ASC 842 provides optional practical expedients in transition. The System elected the package of practical expedients, which permits the System not to reassess under ASC 842 prior conclusions about lease identification, lease classification, and initial direct costs, and the practical expedient not to reassess certain land easements. The adoption of ASC 842 resulted in the addition of approximately \$208,035,000 of right-of-use assets, net of deferred rent, and \$216,305,000 of lease liabilities to the consolidated balance sheet as of July 1, 2019. Certain real estate and medical office buildings were part of a sale-leaseback transaction that was accounted for as a financing transaction prior to adoption. As a result of adoption, the transaction qualified as a sale and a lease. This resulted in an increase in right-of-use assets and lease liabilities of \$39,459,000 and a decrease in net property and equipment and other long-term liabilities of \$56,645,000 and \$63,774,000, respectively, with the remaining \$7,129,000 recorded as a cumulative adjustment to opening net assets. The adoption of ASC 842 also resulted in increased disclosure, including qualitative and quantitative disclosures about the nature, amount, timing, and uncertainty of cash flows arising from leases.

In March 2017, the FASB issued ASU 2017-07, Compensation – Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost. This update changes the presentation requirements of net periodic pension and postretirement

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

benefit costs in the statement of operations and changes in net assets by requiring the service cost component to be presented as part of compensation expense and the remaining components to be presented separately from the service cost component and outside a subtotal of income from operations. The updated guidance is effective for annual periods beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. The System adopted the guidance in ASU 2017-07 on July 1, 2019, using a retrospective approach. The System elected to use the practical expedient that allows the use of the amounts reported in the prior year disclosure to estimate the amount of the retrospective adjustment. As a result of the adoption of ASU 2017-07, CHRISTUS has reported service cost as part of compensation expense and the remaining components of net periodic pension and postretirement benefit costs in other nonoperating loss within the June 30, 2020 and 2019, consolidated financial statements and has also added additional disclosures. In connection with the System's adoption of ASU 2017-07, the System reclassified \$(15,130,000) from employee compensation and benefits expense to other nonoperating gain (loss) for the year ended June 30, 2019.

In November 2016, the FASB issued ASU 2016-18, Restricted Cash, as an update to ASC 230, Statement of Cash Flows. This update requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The System adopted the guidance in ASU 2016-18 on June 30, 2020, using a retrospective approach. As a result of the adoption of ASU 2016-18, CHRISTUS has included restricted cash and cash equivalents in the reconciliation of cash on the consolidated statement of cash flows for the years ended June 30, 2020 and 2019. The adoption of this guidance resulted in an increase to previously reported 2019 net cash provided by operating activities of \$59,266,000 and a corresponding increase to previously reported increase in cash and cash equivalents (which is now captioned increase in cash, cash equivalents, and restricted cash).

In January 2016, the FASB issued ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This update requires equity investments (except those accounted for under the equity method of accounting) to be measured at fair value with changes in fair value recognized in net income and simplifies the impairment assessment of equity investments without readily determinable fair values. The System adopted the guidance in ASU 2016-01 on June 30, 2020, using a modified retrospective approach. Adoption of ASU 2016-01 did not materially impact the System's consolidated financial statements.

Notes to Consolidated Financial Statements (continued)

3. Summary of Significant Accounting Policies (continued)

Pending Accounting Pronouncements

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment, as an update to ASC 350, Intangibles – Goodwill and Other. This update eliminates step 2 of the goodwill impairment test, which required an entity to determine the fair value of individual assets and liabilities of the reporting unit. Under this updated guidance, the impairment amount will be determined using the step 1 comparison of fair value with carrying value. The updated guidance will be effective for the annual and any interim goodwill impairment tests in fiscal years beginning after December 15, 2021. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. CHRISTUS is currently evaluating the impact of this pronouncement on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides guidance for accounting for credit losses on financial instruments. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The updated guidance will be effective for fiscal years beginning after December 15, 2022, including interim periods within that fiscal year. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. CHRISTUS is currently evaluating the impact of this pronouncement on its consolidated financial statements.

4. Revenue Recognition

Patient Service Revenue

CHRISTUS recognizes patient service revenue in the period in which performance obligations under its contracts are satisfied by transferring services to patients. The System measures the performance obligation for inpatient services from admission to the System facility to the point when it is no longer required to provide services to the patient, which is generally at the time of discharge. Performance obligations for inpatient services are satisfied over time during the patients' stay at the applicable facility. For in-house patients, revenue is recognized based on the amount of actual charges incurred as of the end of the reporting period, reduced by an estimate of contractual adjustments based on a combination of negotiated rates and historical experience for the payor class. Performance obligations for outpatient services are generally satisfied on the date

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

of the outpatient visit. Bills to patients and third-party payors are generally sent within a few days or weeks of the inpatient discharge or outpatient visit.

Patient service revenue is reported at amounts that reflect the consideration to which CHRISTUS expects to be entitled for providing patient care. The System's patients include those covered under Medicare, Medicaid, managed care health plans, and commercial insurance companies, as well as uninsured patients. The System has entered into payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. The basis for payment to the System under these agreements includes prospectively determined rates per discharge, discounts from established charges, and negotiated daily rates. Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient diagnosis-related group classification system that is based on clinical, diagnostic, and other factors. Inpatient and outpatient services rendered to Medicaid program beneficiaries are paid under cost reimbursement methodologies, prospectively determined rates per discharge, and prospectively determined or negotiated rates.

The transaction price for each patient is based on the gross charges for services provided, reduced by contractual adjustments and discounts determined based on contractual or negotiated rates as described above. For uninsured and certain underinsured patients, the transaction price is further reduced by implicit price concessions, estimated using historical collection percentages, which reduce the amount of revenue recognized to amounts the System expects to collect.

Revenue under certain third-party payor agreements is subject to audit, retroactive adjustments, and significant regulatory actions. Provisions for third-party payor settlements and adjustments are estimated and recorded in the period the related services are rendered and adjusted in future periods as final settlements are determined. At June 30, 2020 and 2019, the System has estimated third-party settlements, net, of \$32,195,000 and \$61,183,000, respectively, recorded in accounts payable and accrued expenses in the consolidated financial statements. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a possibility that recorded estimates will change by a material amount in the near term. Patient service revenue includes variable consideration for these retroactive revenue adjustments resulting from the settlement of audits, reviews, and investigations using the most likely outcome method.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

For fiscal years 2020 and 2019, revenue increased \$14,824,000 and \$13,146,965, respectively, related to changes in estimates for cost report reopenings, appeals, and tentative and final cost report settlements on filed cost reports, of which some are still subject to audit, additional reopening, and/or appeal.

The transaction price for patient services provided depends greatly upon the System's payor mix, as collections on gross charges can vary significantly, depending on a patient's insurance coverage, or lack thereof, and the extent of amounts due from patients for co-pays, coinsurance, and deductibles. Various factors affect collection trends within each major class of payors. These include general economic conditions, including unemployment rates, which may influence the number of uninsured and underinsured patients; regulatory changes that affect reimbursement rates from governmental programs such as Medicare and Medicaid; and ongoing contract negotiations with managed care health plans and commercial insurance providers. In addition, estimates of implicit price concessions offered to uninsured patients or related to co-pays, coinsurance, and deductibles of patients with insurance are subject to change as historical collection and write-off experience is analyzed on a monthly basis. These changes are recorded as adjustments to the transaction price in the period in which the estimates are revised. Subsequent adjustments that are determined to be the result of an adverse change in the patient's or the payor's ability to pay are recognized as bad debt expense, which is recorded as a component of other operating expenses in the accompanying consolidated statements of operations and changes in net assets.

The following table summarizes the amount of net patient service revenue recognized by payor during the years ended June 30 (in thousands):

	Percentage		Percentage
 2020	of Total	2019	of Total
\$ 1,749,199	34%	\$ 1,754,497	35%
708,504	14	888,520	18
1,775,063	35	1,803,120	36
337,316	7	116,961	2
 238,191	5	202,536	4
4,808,273	95	4,765,634	95
 264,265	5	282,246	5
\$ 5,072,538	100%	\$ 5,047,880	100%
\$ 	\$ 1,749,199 708,504 1,775,063 337,316 238,191 4,808,273 264,265	2020 of Total \$ 1,749,199 34% 708,504 14 1,775,063 35 337,316 7 238,191 5 4,808,273 95 264,265 5	2020 of Total 2019 \$ 1,749,199 34% \$ 1,754,497 708,504 14 888,520 1,775,063 35 1,803,120 337,316 7 116,961 238,191 5 202,536 4,808,273 95 4,765,634 264,265 5 282,246

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

The System also receives payments through state supplemental payment programs, which includes Disproportionate Share (DSH) payments in multiple states, and the 1115(b) Waiver Program (Waiver Program) payments in the state of Texas.

Federal law permits state Medicaid programs to make DSH payments to hospitals that serve a disproportionately large number of Medicaid and low-income patients. These funds are not tied to specific services for Medicaid-eligible patients. The federal government distributes federal Medicaid DSH funds to each state based on a statutory formula. Revenue under the DSH programs is recognized as a component of net patient service revenue over the benefit period when information is received from the states regarding the amount and timing of DSH payments to be received for the applicable period. CHRISTUS believes that its performance obligations are generally satisfied ratably over the applicable period and recognizes revenue on a monthly basis. The System recorded \$149,482,000 and \$122,667,000 in net patient service revenue during fiscal years 2020 and 2019, respectively, related to the DSH program.

In December 2011, the Centers for Medicare & Medicaid Services (CMS) approved the Waiver Program submitted by the Texas Health and Human Services Commission (HHSC). The Waiver Program provides supplemental payments to hospitals through two pools: Uncompensated Care Pool (UC) and the Delivery System Reform Incentive Pool (DSRIP). Both pools replace the former Upper Payment Limit program in Texas. Payments under the Waiver Program are determined in each demonstration year, which aligns with the federal fiscal year. The Waiver Program was scheduled to expire on September 30, 2016; however, CMS approved a 15-month extension that ended December 31, 2017. On December 21, 2017, CMS approved a five-year renewal of the Waiver Program that expires on September 30, 2022. September 30, 2019, marked the completion of the eighth demonstration year.

CMS extended the DSRIP funding pool for four years with the dollar amount of the pool declining each year beginning in the 9th demonstration year until it reaches \$0 in the 11th demonstration year. On January 19, 2018, CMS approved the DSRIP protocols, which cover the requirements for participation in DSRIP for demonstration years seven and eight. Additionally, the protocols for demonstration years nine and ten were approved in September 2019. The System participates in 13 measure bundles as outlined in the protocols. The UC funding pool was extended for the full five-year period, with the level of funding subject to special terms and conditions. The UC funding pool disbursement methodology was revised as part of the extension for years nine and ten.

HHSC provides all Texas hospitals the DSH and UC tools for each demonstration year, which are used to determine qualification for payment under the programs. The 2018, 2019, and 2020 tools

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

have been finalized by HHSC and were used by HHSC in modeling both DSH and UC payments for the seventh, eighth, and ninth demonstration years ended September 30, 2018, 2019, and 2020, respectively. While payments are generally not finalized until the end of the demonstration year, HHSC paid in advance the full expected 2020 DSH and UC payments as of June 30, 2020 in an effort to assist with any cash flow issues hospitals were experiencing due to the novel coronavirus disease 2019 (COVID-19).

Revenue under the waiver program is recognized as a component of net patient service revenue over the applicable demonstration year. CHRISTUS believes that its performance obligations for UC payments are generally satisfied ratably over the applicable period and recognizes revenue on a monthly basis. Performance obligations for DSRIP payments are satisfied based on the status of the selected projects and revenue is recognized ratably for projects that are on track to achieve the required metrics. The System recorded \$289,387,000 and \$348,262,000 in net patient service revenue during fiscal years 2020 and 2019, respectively, related to the Waiver Program. Given the complexity of the ultimate determination of payment due to the System under the Waiver Program, amounts recorded are based on estimates made by management with the assistance of various consultants. As a result, it is at least a possibility that recorded amounts may change by a material amount at the completion of each demonstration year.

The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, participation requirements of government healthcare programs, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has continued with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs, together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Termination of the System's participation in the Medicare or Medicaid programs could have a material impact on the consolidated financial statements.

In addition, government agencies may review the System's compliance with various payment regulations and conduct audits under CMS's Recovery Audit Contractor (RAC), as well as other programs. The results of the enhanced medical necessity reviews and the RAC program audits could have an adverse effect on the System's consolidated financial statements. To the extent these reviews result in an adverse finding, the System may appeal the adverse finding, though it may incur significant legal expense.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Charity Care

The System provides care to many patients who cannot afford to pay and who meet the System's criteria for financial assistance. Charity care services provided to these patients are not reported as patient service revenue, as there is no expectation of payment, and therefore, contracts with these patients do not exist. CHRISTUS estimates the cost of providing charity care using the applicable cost to charge ratios of the hospital participants.

Patient Accounts Receivable

The System grants credit without collateral to its patients, most of whom are local residents of the geographies of the various System healthcare centers and are insured under third-party payor agreements. The mix of accounts receivable, net of applicable allowances, from patients and third-party payors at June 30 was as follows:

	2020	2019
Medicare	32%	32%
Medicaid	10	10
Managed care organizations	35	38
Self-pay	5	5
Others	18	15
	100%	100%

Premium Revenue

The System earns premium revenue from two primary sources: revenues generated by the System's health maintenance organization, and revenues generated under contract with the Department of Defense to administer a Uniformed Services Family Health Plan (USFHP). USFHP premiums are primarily derived through capitated arrangements whereby CHRISTUS earns a negotiated fee per member per month. In return for these premiums, CHRISTUS is responsible for administering covered benefits. Revenue under this contract is recognized on a monthly basis, subject to provisions for retrospective adjustments based primarily on the results of membership audits. USFHP premium revenue was \$135,877,000 and \$131,000,000 during the years ended June 30, 2020 and 2019, respectively.

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Other Revenue

CHRISTUS earns other revenue from management and license fees, memberships, and point of sale transactions, such as cafeterias and gift shops, which are subject to the provisions of ASC 606. Management and license fee contracts include variable consideration as the fees are not fixed but are based on a percentage of revenue. CHRISTUS recognizes revenue when the uncertainty is resolved, which is generally on a monthly basis as actual revenues are known or can be reasonably estimated. CHRISTUS also evaluates the collectibility of each of its management and license fee contracts and applies a constraint, if necessary, to avoid future reversals of revenue. Membership revenues relate primarily to fitness centers operated by various hospitals throughout the System, and are recognized ratably over the membership period. Revenues from point of sale transactions are recognized as incurred. For the year ended June 30, 2020, other revenue included \$128,673,000 related to amounts received under the CARES Act. The System recognizes grant payments under the CARES Act as revenues when there is reasonable assurance that the grant conditions are met. These estimates could change materially based on evolving grant compliance provisions and guidance provided by the U.S. Department of the Treasury, including the notice of reporting requirements released on September 19, 2020. The System will continue to monitor the evolving guidelines and may record adjustments as additional information is released. The System's other revenue also includes equity in (losses) income of unconsolidated organizations, unrestricted donation revenue, rental income, and gains arising from inherent contributions in business combinations and contributions to joint ventures.

Contract Balances

Under the Medicare Advance Payment program, eligible providers may request an advance on up to six months' worth of Medicare reimbursement. Beginning in April 2020, CHRISTUS requested and received approximately \$578,000,000 in Medicare Advance Payments during the year ended June 30, 2020. These payments represent an advance on future reimbursements and the program requires CMS to recoup the payments by withholding future Medicare fee-for-service payments for claims until the full accelerated payment has been recouped. Such accelerated payments are interest free for inpatient acute care hospitals for 12 months and any outstanding balances remaining after 12 months must be repaid or be subjected to a 10.25% annual interest rate. The Medicare Advance Payments are recorded as contract liabilities and are included in deferred revenue on the consolidated balance sheet as of June 30, 2020.

Notes to Consolidated Financial Statements (continued)

5. Cash and Investments

Total cash and investments for the System at June 30, including assets whose use is limited, are as follows (in thousands):

	2020	2019
Cash and cash equivalents	\$ 1,446,300 \$	790,985
Certificates of deposit	27,533	56,614
Domestic equities	151,400	112,788
International equities	24,865	22,234
Fixed-income securities	313,002	273,234
U.S. government securities	224,667	230,065
Mutual funds and exchange-traded funds:		
Domestic equity funds	114,648	76,908
International equity funds	135,738	88,503
Fixed-income funds	185,158	175,774
Risk parity, blended, and other funds	53,025	58,773
Equity investments in managed funds:		
Fixed-income funds	96,722	80,891
Hedge funds	183,371	203,454
Private equity, real estate, and other	32,693	27,094
-	\$ 2,989,122 \$	2,197,317

The System's investments are subject to various types of risks, as explained below.

Fixed Income

This investment class includes investments in various fixed-income instruments that include investment-grade and high-yield domestic and international bonds, preferred stocks, mortgage pools, master limited partnership units, and bonds issued by U.S. government agencies. The fixed-income investments are exposed to various kinds and levels of risk, including interest rate risk, credit risk, foreign exchange risk, and liquidity risk.

Notes to Consolidated Financial Statements (continued)

5. Cash and Investments (continued)

Equities

This investment class consists primarily of common and preferred equity securities of domestic and foreign companies. These securities trade through the major public domestic and international exchanges. The equity securities investments are exposed to various risks, including market risk; individual security risk; foreign exchange risk; and, for common equity of companies with a small market capitalization, liquidity risk.

Mutual Funds and Exchange-Traded Funds

This investment class includes investments in mutual funds, exchange-traded funds, common collective trust funds, and other similar investment funds that generally hold investments in marketable debt and equity securities. Investments in mutual funds, exchange-traded funds, common collective trust funds, and similar funds in this category are exposed to various risks, including market risk and risks associated with the specific securities held within the funds. Certain funds within this category are valued based on amounts reported to the System by the fund managers, generally in the form of net asset value (NAV) per share or an equivalent measure.

Equity Investments in Managed Funds

Equity investments in managed funds include investments in limited liability partnerships or corporations and other alternative investments. The System's equity investments in managed funds are recorded based on the System's share of the underlying value of marketable securities and nonmarketable interests held by these funds as reported to the System by the fund managers, generally in the form of NAV or an equivalent measure. The underlying securities in managed funds could include marketable debt and equity securities, nonmarketable securities, derivative instruments, or any other investment securities determined at the discretion of the fund managers. These investments are recorded at amounts confirmed by fund managers, and there can be no assurance such reported amounts will ultimately be realized.

These funds are invested with external investment managers who invest primarily in various categories, including fixed income, long and short equity positions, managed futures, emerging markets, distressed enterprises, arbitrage, risk parity, private equity, and real estate positions.

Notes to Consolidated Financial Statements (continued)

5. Cash and Investments (continued)

These investments are domestic and international in nature, are illiquid, and returns may not be realized for a period of several years after the investments are made. The risks associated with these investments are numerous, resulting in a greater likelihood of losing invested capital. The risks include the following:

Non-Regulation Risk – Some of these funds are not required to register with the Securities and Exchange Commission and are not subject to regulatory controls.

Managerial Risk – Fund managers may fail to produce the intended returns and are not subject to oversight.

Minimal Liquidity – Many funds impose lockup periods that prevent investors from redeeming their shares or impose penalties to redeem.

Limited Transparency – As unregistered investment vehicles, funds are not required to disclose the holdings in their portfolios to investors.

Investment Strategy Risk – The funds often employ sophisticated, risky investment strategies; are speculative; and may use leverage, which could result in volatile returns.

At June 30, 2020, the System had commitments to fund equity investments in private equity funds totaling \$15,994,000, excluding commitments to fund equity investments in private equity funds held by the CHRISTUS Health Cash Balance Plan (the Cash Balance Plan – see Note 12).

Notes to Consolidated Financial Statements (continued)

5. Cash and Investments (continued)

Assets whose use is limited or restricted consisted of the following at June 30 (in thousands):

	 2020	2019
Assets whose use is limited or restricted, required for current bond indenture and self-insurance liabilities Other investments, internally designated for capital	\$ 52,685	\$ 65,872
expansion and other purposes	532,132	457,991
Under bond indenture agreement – held by trustee Under liability retention and self-insurance funding	71,089	125,447
arrangement – held by trustee	19,894	20,514
Under Emerald Assurance funding arrangements	103,011	116,517
Restricted cash and investments	 56,936	77,163
Total assets whose use is limited or restricted	\$ 835,747	\$ 863,504

Restricted cash and investments relate primarily to investments required to be maintained in perpetuity under the System's endowments, or to cash and investments restricted by donors for the acquisition of capital assets.

Investment returns and gains for assets limited as to use, cash equivalents, and other unrestricted investments consisted of the following for the fiscal years ended June 30 (in thousands):

		2020	2019
Operating interest and dividend income Operating gain, realized and unrealized	\$	14,706 \$ 904	12,352 5,830
Equity investment gain on managed funds		736	2,293
Total operating investment income	***************************************	16,346	20,475
Nonoperating interest and dividend income		18,747	23,292
Nonoperating gain, realized and unrealized		40,040	22,520
Equity investment (loss) gain on managed funds		(3,206)	7,543
Net swap agreement activity		(70,469)	(46,932)
Total nonoperating investment (loss) gain, net		(14,888)	6,423
Total investment gain, net	\$	1,458 \$	26,898

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements

The three-level valuation hierarchy for disclosure of fair value measurements is based on the transparency of inputs to the valuation of an asset or liability as of the reporting date. The three levels are defined as follows:

- Level 1 Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities at the reporting date.
- Level 2 Inputs to the valuation methodology other than quoted market prices included in Level 1 that are observable for the asset or liability. Level 2 pricing inputs include quoted prices for similar assets and liabilities in active markets and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
- Level 3 Inputs that are generally unobservable and typically reflect management's
 estimate of assumptions that market participants would use in pricing the asset or liability.

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. There were no significant transfers between levels during the fiscal years ended June 30, 2020 or 2019.

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

The following tables present the financial instruments carried at fair value as of June 30 (in thousands) by the valuation hierarchy (as described above):

				20	20		
	Level 1			Level 2		Level 3	Total
Assets							
Cash and cash equivalents	\$	1,446,300	\$	_	\$	- \$	1,446,300
Investments:							
Certificates of deposit		_		27,533		_	27,533
Domestic equities		151,400		_		_	151,400
International equities		24,865		_		_	24,865
Fixed-income securities		_		313,002		_	313,002
U.S. government securities		_		224,667		_	224,667
Mutual and exchange-traded funds:							
Domestic equity funds		32,078		_		_	32,078
International equity funds		114,745		_		_	114,745
Fixed-income funds		96,334		_		_	96,334
Risk parity, blended, and other							
funds		53,025		_		_	53,025
	\$	1,918,747	\$	565,202	\$	_	2,483,949
Investments measured at net asset							
value or equivalent:							
Equity funds							103,564
Fixed-income funds							111,963
Hedge funds							52,521
Private equity, real estate, and							
other funds							1,615
Total assets at fair value						\$	2,753,612
							
Liabilities							
Interest rate swap agreements	\$	_	\$	187,339	\$	- \$	187,339
Total liabilities at fair value	\$	_	\$	187,339	\$	- \$	187,339

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

			20	119		
		Level 1	Level 2		Level 3	Total
Assets	-					
Cash and cash equivalents	\$	790,985	\$ _	\$	- \$	790,985
Investments:						
Certificates of deposit		_	56,614		_	56,614
Domestic equities		112,788	_		_	112,788
International equities		22,234	_		_	22,234
Fixed-income securities		_	273,234		_	273,234
U.S. government securities		_	230,065		_	230,065
Mutual and exchange-traded funds:						
Domestic equity funds		31,053	_		_	31,053
International equity funds		76,603	_		_	76,603
Fixed-income funds		90,455	_		_	90,455
Risk parity, blended, and other						
funds		58,773	_		_	58,773
	\$	1,182,891	\$ 559,913	\$	_	1,742,804
Investments measured at net asset						
value or equivalent:						
Equity funds						57,755
Fixed-income funds						115,124
Hedge funds						57,420
Private equity, real estate, and						
other funds						1,684
Total assets at fair value					\$	1,974,787

Liabilities						
Interest rate swap agreements	\$	_	\$ 126,772	\$	- \$	126,772
Total liabilities at fair value	\$		\$ 126,772	\$	- \$	126,772

The tables above include equity investments in managed funds held within the System's foundations and captive insurer. Remaining equity investments in managed funds held by other System entities of \$235,510,000 and \$222,390,000 at June 30, 2020 and 2019, respectively, are not included in this table since they are accounted for using the equity method of accounting.

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

The valuation methodologies used for instruments measured at fair value as presented in the tables above are as follows:

- Investments Investments valued at quoted prices available in an active market are classified within Level 1 of the valuation hierarchy. Investments valued based on evaluated bid prices provided by third-party pricing services, where quoted market prices are not available, are classified within Level 2 of the valuation hierarchy. Investments measured at fair value using net asset value per share or its equivalent as a practical expedient are not categorized within the fair value hierarchy. These investments consist of hedge funds, commodity funds, common collective trust funds, private equity funds, real estate funds, and some equity and fixed-income funds.
- Interest rate swap agreements Interest rate swap agreements are valued using third-party models that use observable market conditions as their input and are classified within Level 2 of the valuation hierarchy.

At June 30, 2020 and 2019, the System's financial instruments included cash and cash equivalents, accounts receivable, assets limited as to use, accounts payable and accrued expenses, estimated third-party payor settlements, and long-term debt. The carrying amounts reported in the consolidated balance sheets for these financial instruments, except for long-term debt, approximate their fair values due to their short-term nature.

Notes to Consolidated Financial Statements (continued)

7. Leases

The System utilizes operating and finance leases for the use of various facilities and equipment. All lease agreements generally require the System to pay maintenance, repairs, property taxes, and insurance costs, which are variable amounts based on actual costs incurred during each applicable period. Such costs are not included in the determination of the right-of-use asset or lease liability. Variable lease cost also includes escalating rent payments that are not fixed at commencement but are based on an index that is determined in future periods over the lease term based on changes in the consumer price index or other measure of cost inflation. Certain equipment leases include non-lease components such as minimum purchase requirements for consumable products associated with the equipment. The System has elected the practical expedient that allows lessees to choose not to separate lease and non-lease components by class of underlying asset and are applying this expedient to all relevant asset classes.

Leases may include one or more options to renew. The exercise of lease renewal options is at the System's sole discretion. In general, the System does not consider renewal options to be reasonably likely to be exercised; therefore, renewal options are generally not recognized as part of right-of-use assets and lease liabilities. Certain leases also include options to purchase the leased asset. The System's financing lease liabilities include \$42,019,000 for the lease of the Sulphur Springs Hospital from Hopkins County Hospital District, the System's partner in the CHRISTUS Hopkins Health Alliance joint venture.

The components of lease cost, for the twelve months ended June 30, consisted of the following (in thousands):

	2020			
Operating lease cost	\$	55,963		
Finance lease cost:				
Amortization of right-of-use assets		6,898		
Interest on lease liabilities		11,667		
Total finance lease cost		18,565		
Short-term and variable lease cost		46,784		
Total lease cost	\$	121,312		

Notes to Consolidated Financial Statements (continued)

7. Leases (continued)

Supplemental cash flow and other information related to leases as of and for the twelve months ended June 30 are as follows (dollars in thousands):

	 2020
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases Operating cash flows from finance leases Financing cash flows from finance leases	\$ 55,916 11,667 6,349
Right-of-use assets obtained in exchange for new operating leases Right-of-use assets obtained in exchange for new financing leases	38,555 965
Weighted average remaining lease term: Operating leases Finance leases	6.6 years 14.1 years
Weighted average discount rate: Operating leases Finance leases	2.57% 10.47

Notes to Consolidated Financial Statements (continued)

7. Leases (continued)

Future undiscounted cash flows and maturities of lease liabilities at June 30, 2020, are presented in the following table (in thousands):

- , , , , , , , , , , , , , , , , , , ,	Operating Leases			Finance Leases		Total
2021	\$	53,979	\$	18,635	\$	72,614
2022	4	48,361	•	18,873	*	67,234
2023		42,147		17,907		60,054
2024		34,125		17,742		51,867
2025		21,115		17,728		38,843
Thereafter		60,442		124,811		185,253
Total minimum lease payments		260,169		215,696		475,865
Less imputed interest		(20,666)		(98,560)		(119,226)
Total lease liabilities		239,503		117,136		356,639
Less current portion		(48,849)		(7,179)		(56,028)
Long-term lease liabilities	\$	190,654	\$	109,957	\$	300,611

Certain real estate and medical office buildings acquired from Good Shepherd Health System were part of a sale-leaseback transaction that was accounted for as a financing transaction as of July 1, 2019, due to continuing involvement based on certain contingencies in the agreements, which precluded the de-recognition of the assets when the transaction closed. Upon adoption of ASC 842, the System reevaluated the classification of these financing arrangements concluding that these financing arrangements qualify as a sale and operating lease under ASC 842.

The change in classification resulted in an increase in right-of-use assets and lease liabilities of \$39,459,000 and a decrease in net property and equipment and other long-term liabilities of \$56,645,000 and \$63,774,000, respectively, with the remaining \$7,129,000 recorded as a cumulative adjustment to net assets.

Notes to Consolidated Financial Statements (continued)

8. Property and Equipment

Property and equipment at June 30 consisted of the following (in thousands):

2020	2019
\$ 229,286	\$ 219,788
89,936	88,085
3,531,831	3,471,335
1,599,653	1,582,602
(2,831,868)	(2,782,890)
2,618,838	2,578,920
187,362	146,606
\$ 2,806,200	\$ 2,725,526
	\$ 229,286 89,936 3,531,831 1,599,653 (2,831,868) 2,618,838

Depreciation expense for the System for fiscal years 2020 and 2019 totaled \$243,969,000 and \$227,273,000, respectively.

At June 30, 2019, assets capitalized under capital leases as reflected in the accompanying consolidated balance sheet included \$117,836,000 of buildings and fixed equipment and \$27,436,000 of major movable equipment. The accumulated depreciation related to assets under capital leases was \$66,390,000 as of June 30, 2019. Depreciation of assets under capital leases is included in depreciation expense for the year ended June 30, 2019.

Notes to Consolidated Financial Statements (continued)

9. Investments in Unconsolidated Organizations

The System has investments in unconsolidated organizations of \$238,682,000 and \$234,059,000 at June 30, 2020 and 2019, respectively. Differences between the carrying amounts of the System's investments and the underlying equity in the net assets of the investees total \$71,206,000 and \$74,467,000 at June 30, 2020 and 2019, respectively. These differences are attributed to the excess fair value over book value of intangible assets at the investee level, and are being reduced as an adjustment to equity earnings over the life of the related contracts. The intangible is reviewed for impairment on an annual basis. The following table summarizes the investments in unconsolidated organizations as of June 30 (in thousands):

	Accounting			
Investee	Policy	2020	2019	
U.C. CHRISTUS Salud SpA	Equity method \$	174,934 \$	172,802	
Sinergia Global en Salud SAS	Equity method	_	_	
Coomeva Medicina Prepagada	Cost	11,457	11,457	
Southwest Post-Acute Care Partnership	Equity method	19,419	17,815	
HealthSouth Rehabilitation Hospital	Equity method	9,994	11,078	
CS/USP Surgery Centers, L.P.	Equity method	6,891	6,856	
Other	Equity method	15,987	14,051	
Total	\$	238,682 \$	234,059	

U.C. CHRISTUS Salud SpA

CHRISTUS owns a 50% noncontrolling interest in U.C. CHRISTUS Salud SpA (CHRISTUS Salud), which owns and operates certain hospital, clinic, and other healthcare facilities in Chile. CHRISTUS Salud also manages the healthcare operations of Pontifica Universidad Catolica de Chile (PUC), which owns the other 50% ownership interest. Note 19 has additional discussion of the System's international operations.

Notes to Consolidated Financial Statements (continued)

9. Investments in Unconsolidated Organizations (continued)

During 2020 and 2019, CHRISTUS made additional capital contributions to CHRISTUS Salud of \$10,585,000 and \$33,659,000, respectively. The System's share of (losses) income from the operations for the fiscal years ended June 30, 2020 and 2019, was \$(8,453,000) and \$4,035,000, respectively.

Sinergia Global en Salud SAS and Coomeva Medicina Prepagada

Effective June 14, 2016, CHRISTUS signed definitive agreements with Cooperativa Medica del Valle y de Profesionales de Colombia (Coomeva) in Colombia to invest in certain of Coomeva's healthcare operations. CHRISTUS owns a 50% noncontrolling ownership interest in Sinergia Global en Salud SAS (Sinergia) and a 10% noncontrolling ownership interest in Coomeva Medicina Prepagada (MP). Note 19 has additional discussion of the System's international operations.

The System's investment in Sinergia is accounted for under the equity method of accounting because CHRISTUS can exercise significant influence over Sinergia's operations. The System's investment in MP is accounted for at cost less impairments, if any, because CHRISTUS does not exercise significant influence over MP's operations and the investment in MP does not have a readily determinable fair value. The System's recorded investment in Sinergia was \$16,885,000 at June 30, 2019, prior to the consideration of impairment. During fiscal year 2019, CHRISTUS performed a review for impairment and concluded the investment was not recoverable. The System recorded an impairment of \$16,885,000 resulting in a carrying value of the investment in Sinergia of \$0 at June 30, 2019. The investment remains at \$0 as of June 30, 2020. During the fiscal years ended June 30, 2020 and 2019, CHRISTUS reported losses from its equity method investment in Sinergia of \$0 and \$20,630,000, respectively, inclusive of impairment charges. In 2019, CHRISTUS and Coomeva also contributed an additional \$10,476,000 each as part of a capital call that did not affect ownership percentages. Dividends of \$474,000 and \$911,000 were declared by MP and recorded as other revenue during the fiscal years ended June 30, 2020 and 2019, respectively.

Notes to Consolidated Financial Statements (continued)

9. Investments in Unconsolidated Organizations (continued)

Southwest Post-Acute Care Partnership

CHRISTUS Continuing Care has a 40% noncontrolling interest in Southwest Post-Acute Care Partnership, LLC. The System's recorded investment was \$19,419,000 and \$17,815,000 at June 30, 2020 and 2019, respectively. The System recorded its share of income from operations during the fiscal years ended June 30, 2020 and 2019, of \$1,604,000 and \$682,000, respectively.

HealthSouth Rehabilitation Hospital

CHRISTUS Trinity Mother Frances Health System owns 50% of HealthSouth Rehabilitation Hospital – Tyler d/b/a/ Trinity Mother Frances Rehabilitation Hospital (HealthSouth). Because CHRISTUS can exercise significant influence over the operations of HealthSouth but does not control HealthSouth, this investment is accounted for using the equity method of accounting. The System's recorded investment was \$9,994,000 and \$11,078,000 at June 30, 2020 and 2019, respectively. The System recorded its share of income from operations during the fiscal years ended June 30, 2020 and 2019, of \$3,912,000 and \$4,844,000, respectively.

CS/USP Surgery Centers, L.P.

CHRISTUS Spohn Health System Corporation has a 50% ownership interest in a Texas limited liability partnership with United Surgical Partners International, Inc. for the purpose of owning and operating ambulatory surgery centers in Corpus Christi, Texas. The venture consists of two surgery centers near the campus of Spohn Shoreline, Corpus Christi Outpatient Surgery and SurgiCare, and one endoscopy center. CHRISTUS' recorded investment, accounted for under the equity method, was \$6,891,000 and \$6,856,000 at June 30, 2020 and 2019, respectively. The System recorded its share of income from operations during the fiscal years ended June 30, 2020 and 2019, of \$1,467,000 and \$1,391,000, respectively.

CHRISTUS and its affiliates hold immaterial investments in other unconsolidated subsidiaries. No other single investment balance exceeded \$5,000,000 at both June 30, 2020 and 2019.

Notes to Consolidated Financial Statements (continued)

10. Long-Term Debt

Long-term debt at June 30 consisted of the following (in thousands):

		2020	2019
Obligations issued under the CHRISTUS Health Master Trust			
Indenture:			
Revenue bonds, in variable-rate demand mode, with			
weighted average interest rates of 1.16% and 1.59% in			
fiscal years 2020 and 2019, respectively, due in annual			
installments through July 1, 2047 (Series 2008C and			
2009B)	\$	223,015 \$	223,015
Revenue bonds, in auction mode, with weighted average			
interest rates of 1.57% and 1.89% in fiscal years 2020 and			
2019, respectively, due in annual installments through		127 000	127 700
July 1, 2031 Payanya handa in fixed rate made hearing interest from		127,900	137,700
Revenue bonds, in fixed-rate mode, bearing interest from 4.50% to 5.25%, due in annual installments through			
July 1, 2048		578,155	597,640
Direct-placement notes due in annual installments through		570,155	557,040
July 1, 2041		94,050	102,125
Tax-exempt bank note due in annual installments through		- 1,	,
July 1, 2039		57,105	57,105
Taxable bonds due as a balloon payment on July 1, 2028		339,536	339,536
Bank line of credit		33,000	_
Other notes (including capital lease obligations at June 30,		·	
2019)		92,941	157,721
		1,545,702	1,614,842
Premiums, net, on long-term debt		40,262	43,692
Unamortized deferred financing costs		(9,194)	(10,209)
		1,576,770	1,648,325
Less current portion, including amounts subject to remarketing		10 = 0 < 1	7 d a d a 45
agreements		(87,864)	(41,116)
Total long-term debt	<u>\$</u>	1,488,906 \$	1,607,209

Notes to Consolidated Financial Statements (continued)

10. Long-Term Debt (continued)

According to the terms of the CHRISTUS Health Master Trust Indenture (CHRISTUS MTI), the CHRISTUS Health Obligated Group (Obligated Group) consists of CHRISTUS and the following entities: CHRISTUS Spohn Health System; CHRISTUS Health Southeast Texas; CHRISTUS Santa Rosa Health Care Corporation; CHRISTUS Health Ark-La-Tex; CHRISTUS Health Northern Louisiana; CHRISTUS Health Central Louisiana; Mother Frances Hospital Regional Healthcare Center; and, effective October 30, 2018, The Good Shepherd Hospital, Inc.; CHRISTUS Good Shepherd Medical Center; and Good Shepherd Health System, Inc. Certain entities of CHRISTUS that are otherwise included in the consolidated financial statements of CHRISTUS are excluded from the Obligated Group. As of June 30, 2020, these entities include, but are not limited to, certain CHRISTUS Good Shepherd Health System entities; CHRISTUS Health Southwestern Louisiana; CHRISTUS Hopkins Health Alliance; certain entities within CHRISTUS Trinity Mother Frances Health System (TMF); CHRISTUS Health Liability Retention Trust; Emerald Assurance; CHRISTUS St. Vincent Regional Medical Center; CHRISTUS Physician Group; CHRISTUS Health Plan, CHRISTUS Continuing Care; CHRISTUS Health Gulf Coast; CHRISTUS Muguerza, S.A. de C.V.; CHRISTUS Health Strategic Growth; Amatista Financing Company, Ltd.; CHRISTUS Health Latin America; CHRISTUS Health Chile SpA; and various partnerships and philanthropic foundations.

Under the provisions of the CHRISTUS MTI, the obligations of CHRISTUS and the other members of the Obligated Group are secured by a pledge of gross revenues. Additionally, each member of the Obligated Group has undertaken certain covenants, including the following: to ensure the payment of debt service; to ensure the payment of taxes and other claims; to deliver compliance statement(s); to preserve corporate existence; to maintain books and records subject to inspection by the Master Trustee; to maintain insurance; to conform to defined lien limitations; to establish adequate service rates; to maintain a sufficient debt service coverage and indebtedness ratio; to maintain a required aggregate amount of unrestricted cash and investments; and to adhere to certain defined conditions with respect to consolidation, merger, conveyance, or transfer and admission or withdrawal of Obligated Group members pursuant to the CHRISTUS MTI, insurer, and letter of credit bank agreements.

CHRISTUS has letter of credit bank agreements on Series 2008C and 2009B variable-rate demand bonds. The Series 2008C-1 bonds have an outstanding amount of \$41,435,000 and are supported by a line of credit provided by Sumitomo Mitsui Banking Corporation, acting through its New York branch, that expires on September 20, 2022. The 2008C-2 bonds have an outstanding amount of \$38,305,000 and are supported by a letter of credit provided by The Bank of New York Mellon

Notes to Consolidated Financial Statements (continued)

10. Long-Term Debt (continued)

that expires on June 23, 2021. The 2008C-3 bonds have an outstanding amount of \$41,030,000, and the 2008C-4 bonds have an outstanding amount of \$38,440,000. The 2008C-3 and 2008C-4 bonds are supported by a letter of credit provided by Bank of Montreal, acting through its Chicago branch, that expires on April 25, 2022. The Series 2009B variable-rate demand bonds have an outstanding amount of \$63,805,000 and are supported by a letter of credit provided by The Bank of New York Mellon that expires on January 31, 2022.

On October 30, 2018, CHRISTUS issued the Series 2018A-E bonds, consisting of \$509,865,000 of tax-exempt revenue and refunding bonds, and \$339,536,000 of taxable revenue and refunding bonds (the Series 2018 Bonds). The Series 2018 Bonds have an outstanding amount of \$839,501,000 at June 30, 2020. The Series 2018 Bonds are fixed-rate obligations, comprising both serial and term bonds carrying interest rates ranging from 4.0% to 5.0% and maturing in various amounts through fiscal year 2049. Proceeds of the Series 2018 Bonds were used, in part, to defease and/or repay \$305,090,000 of outstanding bonds and refund amounts outstanding on an existing line of credit, and CHRISTUS recorded a loss on the extinguishment of this debt of \$18,166,000 for the year ended June 30, 2019, which is included in other nonoperating loss on the consolidated statement of operations. In connection with the bond issuance, The Good Shepherd Hospital, Inc.; CHRISTUS Good Shepherd Medical Center; and Good Shepherd Health System, Inc. were added to the CHRISTUS Health Obligated Group.

On April 2, 2019, CHRISTUS issued the Series 2019A bonds, consisting of \$50,520,000 of tax-exempt revenue and refunding bonds. The Series 2019A bonds have an outstanding amount of \$50,520,000 at June 30, 2020. The Series 2019A bonds are fixed-rate obligations, comprising serial and term bonds carrying interest rates of 5% and maturing in various amounts through fiscal year 2049. Proceeds of the Series 2019 Bonds were used to defease a portion of the Series 2009A bonds and CHRISTUS recorded a loss on the extinguishment of this debt of \$2,182,000 for the year ended June 30, 2019, which is included in other nonoperating loss on the consolidated statement of operations.

In fiscal 2018, the System entered into a line of credit with Sumitomo Mitsui Banking Corporation – New York Operations for \$150,000,000. The line of credit carries a variable interest rate equal to the one-month London Interbank Offered Rate (LIBOR) plus 0.625%, and terminates on October 29, 2021. At June 30, 2020 and 2019, CHRISTUS had \$33,000,000 and \$0, respectively, drawn against the line of credit. In fiscal 2020, the System entered into a line of credit with JPMorgan Chase Bank, National Association for \$100,000,000. The line of credit carries a variable interest rate equal to the one-month LIBOR plus 1.375%, and terminates on June 11, 2021. At June 30, 2020, CHRISTUS had \$0 drawn against the line of credit.

Notes to Consolidated Financial Statements (continued)

10. Long-Term Debt (continued)

Other notes and capital lease obligations were \$92,941,000 and \$157,721,000 as of June 30, 2020 and 2019, respectively. Other notes account for \$92,941,000 and \$40,033,000 of that balance as of June 30, 2020 and 2019, respectively, and include various notes issued primarily to purchase buildings and equipment. Capital lease obligations account for \$117,688,000 of that balance as of June 30, 2019, which included various building and equipment leases.

Principal payments for all long-term debt for the next five years and thereafter are as follows (in thousands):

2021	\$ 49,559
2022	74,525
2023	31,914
2024	27,403
2025	33,921
Thereafter	1,328,380_
Total debt	\$ 1,545,702

11. Derivative Financial Instruments

The System's derivative instruments consist primarily of interest rate swap contracts between the System and third parties (counterparties), which provide for the periodic exchange of payments between the parties based on changes in a defined index and a fixed rate. These swaps expose the System to market risk and credit risk. Credit risk is the risk that contractual obligations of the counterparties will not be fulfilled. Concentrations of credit risk relate to groups of counterparties that have similar economic or industry characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions. Counterparty credit risk is managed by requiring high credit standards for the System's counterparties. The counterparties to these contracts are financial institutions that carry investment-grade credit ratings.

Notes to Consolidated Financial Statements (continued)

11. Derivative Financial Instruments (continued)

Market risk is the adverse effect on the value of a financial instrument that results from a change in interest rates. The market risk associated with interest rate changes is managed by establishing and monitoring parameters that limit the types and degrees of market risk that may be undertaken. Management also mitigates risk through periodic reviews of its derivative positions in the context of its blended cost of capital. As of June 30, 2020 and 2019, CHRISTUS has interest rate swap agreements to manage interest rate risk exposure, not designated as hedging instruments, with a total notional amount of \$893,035,000 and \$902,685,000, respectively.

The following tables summarize the fair value at June 30, 2020 and 2019, and the income (loss) recorded related to the System's derivative instruments as of and for the fiscal years ended June 30, 2020 and 2019 (in thousands):

					Fair	Value	Change in 1	Fair Value	(Paid) Received	
		Terminatior	ì	Notional	June 30,	June 30,				
Counterparty	Description	Date	Agreements	Amount	2020	2019	2020	2019	2020	2019
Interest Rate	Swaps									
Merrill Lynch	Var. basis	2021-2023	6	\$ 470,000	\$ (482)	\$ 1,703	\$ (2,185)	\$ (1,115)	\$ 269 \$	1,249
Wells Fargo	Fixed payor	2031	1	143,775/153,425	(23,509)	(18,287)	(5,222)	(4,924)	(3,214)	(2.553)
Citigroup*	Fixed payor	2047	2	166,100	(97.280)	(65,715)	(31,565)	(20,242)	(4,160)	(3,251)
Citigroup*	Fixed payor	2047	1	113.160	(66.068)	(44,473)	(21,595)	(13,919)	(2,797)	(2,177)
			10 5	893,035/902,685	\$(187,339)	\$(126,772)	\$ (60.567)	\$ (40,200)	\$ (9,902)\$	(6,732)

^{*}Insured by MBIA

CHRISTUS is required to post collateral for negative valuations on each of its swaps according to the terms of (1) the swap insurance agreements, where applicable, and (2) the agreement with each counterparty. CHRISTUS has complied with this requirement. At June 30, 2020 and 2019, no collateral was posted. The System does not anticipate nonperformance by its counterparties.

The fair value of these derivative instruments was a liability of \$187,339,000 and \$126,772,000 at June 30, 2020 and 2019, respectively. The change in value of \$(60,567,000) and \$(40,200,000) for the fiscal years ended June 30, 2020 and 2019, respectively, is combined with the payments, net of receipts, made under the agreements of \$9,902,000 and \$6,732,000 for the fiscal years ended June 30, 2020 and 2019, respectively. This total is included in nonoperating investment (loss) gain, net, in the consolidated statements of operations and changes in net assets.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans

Defined Benefit Plans

Cash Balance Plan

The System has established a noncontributory, defined benefit retirement plan that operates as a cash balance plan and covers substantially all CHRISTUS employees who had met age and service requirements as of December 31, 2012. On October 23, 2012, the CHRISTUS board approved the closing of the plan to new participants, effective January 1, 2013.

The plan benefits are calculated based on a cash balance formula wherein participants earn an annual accrual based on compensation and participation account balances accrue interest at a rate that tracks ten-year treasury notes; the maximum rate is 8%. On January 29, 2019, the CHRISTUS board approved a plan amendment to freeze the Cash Balance Plan effective July 1, 2019. As a result of this amendment, the projected benefit obligation increased by approximately \$37,849,000, which will be amortized as a component of net periodic benefit cost over its actuarially determined life.

Mother Frances Hospital Defined Benefit Pension Plan

The System administers the Mother Frances Hospital Defined Benefit Pension Plan (TMF Plan), which covers all employees who meet the eligibility requirements. The plan was frozen as of December 31, 2009.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The measurement date for the Cash Balance Plan and the TMF Plan (collectively, the Defined Benefit Plans) is June 30. Components of net periodic benefit credit for the fiscal years ended June 30 consisted of the following (in thousands):

	 Cash Balanc	e Plan	TMF Plan		
	 2020	2019	2020	2019	
Service cost	\$ - \$	13,871 \$	- \$	_	
Interest cost	27,933	34,201	5,654	6,500	
Expected return on assets	(45,726)	(50,013)	(8,120)	(7,192)	
Amortization of prior service credit	1,147	(10,798)	_		
Recognized net actuarial					
loss (gain)	2,852	13,411	_	(223)	
Curtailment credit	_	(1,016)	_		
Net periodic benefit credit	\$ (13,794) \$	(344) \$	(2,466) \$	(915)	

The components of net periodic benefit credit, other than service cost, are recorded in other nonoperating gain (loss) in the accompanying consolidated statements of operations and changes in net assets. Service cost is recorded as a component of employee compensation and benefits. CHRISTUS uses a full yield curve "spot rate" approach that applies the specific spot rates along the yield curve to the plans' projected cash flows in order to estimate the service and interest cost components of net periodic benefit credit.

During fiscal 2019, the Cash Balance Plan includes a curtailment credit recorded in connection with a remeasurement of plan liabilities resulting from the decision to amend and freeze the plan.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The following table sets forth the changes in benefit obligation, changes in plan assets, and funded status of the Defined Benefit Plans measured as of June 30 (in thousands):

	Cash Balance Plan					TMF Plan		
		2020		2019		2020	2019	
Changes in benefit obligation								
Benefit obligation – beginning of year	\$	975,189	\$	934,896	\$	182,943 \$	168,042	
Service cost		_		13,871		_	_	
Interest cost		27,933		34,201		5,654	6,500	
Plan amendments		_		37,849		_	_	
Actuarial (gain) loss		(4,568)		5,233		19,691	14,939	
Liability gain due to curtailment		_		(2,044)		_	_	
Benefits paid		(50,951)		(48,817)		(6,787)	(6,538)	
Benefit obligation – end of year	\$	947,603	\$	975,189	\$	201,501 \$	182,943	

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

	Cash Balance Plan					TMF PI	an
		2020		2019		2020	2019
Changes in plan assets							
Fair value of plan assets – beginning							
of year	\$	858,634	\$	858,386	\$	146,897 \$	135,996
Actual return on plan assets		5,889		42,065		4,317	8,439
Employer contributions		3,000		7,000		6,750	9,000
Benefits paid		(50,951)		(48,817)		(6,787)	(6,538)
Fair value of plan assets – end of year	\$	816,572	\$	858,634	\$	151,177 \$	146,897
Funded status	\$	(131,031)	\$	(116,555)	\$	(50,324) \$	(36,046)
Amounts recognized in net assets without donor restrictions: Unrecognized net actuarial							
loss (gain)	\$	224,061	\$	191,644	\$	13,452 \$	(10,042)
Unrecognized prior service cost		36,606		37,753		_	
Total recognized in net assets without							
donor restrictions	\$	260,667	\$	229,397	\$	13,452 \$	(10,042)

Amounts recognized in net assets without donor restrictions expected to be recognized in net periodic benefit (credit) cost for the Defined Benefit Plans during fiscal 2021 are \$5,065,000.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The following table represents the changes to the Defined Benefit Plans' assets and projected benefit obligation recognized in net assets without donor restrictions for the fiscal years ended June 30 (in thousands):

Cash Balance Plan				TMI	an	
	2020		2019	2020		2019
\$	35,269	\$	13,181 \$	23,494	\$	13,692
	_		37,849	_		_
	(2,852)		(13,411)	_		223
	(1,147)		10,798	_		_
	-		(1,028)	_		
\$	31,270	\$	47,389 \$	23,494	\$	13,915
	\$	2020 \$ 35,269 - (2,852) (1,147) -	2020 \$ 35,269 \$ - (2,852) (1,147) -	2020 2019 \$ 35,269 \$ 13,181 \$ 37,849 (2,852) (13,411) (1,147) 10,798 - (1,028)	2020 2019 2020 \$ 35,269 \$ 13,181 \$ 23,494 - 37,849 - (2,852) (13,411) - (1,147) 10,798 - - (1,028) -	2020 2019 2020 \$ 35,269 \$ 13,181 \$ 23,494 \$ - - 37,849 - (2,852) (13,411) - (1,147) 10,798 - - (1,028) -

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

As of June 30, 2020 and 2019, the Defined Benefit Plans had accumulated benefit obligations of \$1,149,104,000 and \$1,158,132,000, respectively. Assumptions used to determine benefit obligations and net periodic benefit (credit) cost for the fiscal years were as follows:

	Cash Balance Plan		TMF I	Plan
	2020	2019	2020	2019
Benefit obligations:				
Discount rate	2.66%	3.45%	2.84%	3.62%
Rate of compensation increase	N/A	N/A	N/A	N/A
Net periodic benefit (credit) cost:				
Discount rate ¹	3.45	4.17^{1}	3.62	4.25
Discount face	J. T.J	3.70^{1}	5.02	7.23
Expected long-term return on				
plan assets	5.50	6.00	5.50	5.25
Rate of compensation increase	N/A	3.71	N/A	N/A

¹ The discount rate for the Cash Balance Plan for fiscal 2019 was reset at the time of the remeasurement of the benefit obligation resulting from the decision to freeze the plan.

Investment Policy and Asset Allocations

CHRISTUS Health Cash Balance Plan

The investment objective with regard to the plan assets is one of long-term capital appreciation and generation of a stream of current income. This balanced approach is expected to earn long-term total returns, consisting of capital appreciation and current income, which are commensurate with the expected rate of return used by the plans.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The investment policies and strategies for the assets of the Cash Balance Plan incorporate a well-diversified approach that is expected to generate long-term returns from capital appreciation and a growing stream of current income. This approach recognizes that assets are exposed to risk and the market value of the plan assets may fluctuate from year to year. Risk tolerance is determined based on the plan's financial stability and the ability to withstand return volatility. In developing the expected return on plan assets, the System evaluates the historical performance of total plan assets, the relative weighting of plan assets, interest rates, economic indicators, and industry forecasts. In line with the investment return objective and risk parameters, the mix of assets includes a diversified portfolio of equity, fixed-income, and alternative investments. Equity investments include international stocks and a blend of domestic growth and value stocks of various sizes of capitalization. The aggregate asset allocation is rebalanced as needed, but not less than on an annual basis.

The asset allocations for the Cash Balance Plan at June 30, by asset category, are detailed below (in thousands).

	 2020	2019
Cash and cash equivalents	\$ 83,527 \$	112,672
Domestic equities	35,640	49,676
International equities	20,508	24,261
Fixed-income securities	23,724	21,966
Mutual funds and exchange-traded funds:		
Domestic equity funds	31,225	38,849
International equity funds	58,352	52,935
Fixed-income funds	74,266	68,542
Risk parity, blended, and other funds	31,083	21,804
Equity investments in managed funds:		
Fixed-income funds	242,327	205,363
Hedge funds	89,692	107,920
Private equity, real estate, and other	125,908	154,143
Other	320	503
Total	\$ 816,572 \$	858,634

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The target allocation of plan assets by asset category for the Cash Balance Plan is as follows as of June 30:

	2020	2019
Allocation of plan assets by asset category:	•	
Cash and cash equivalents	<i>−</i> %	<i>−</i> %
Equity securities and equity funds	15	15
Fixed-income securities and fixed-income funds	30	30
Equity investments in managed funds (Note 5)	55	55
Total	100 %	100 %

The value of the plan assets measured at fair value on a recurring basis was determined using the valuation inputs described in Note 6 and categorized at June 30, 2020, as follows (in thousands):

	Level 1		Level 2		Level 3			Total
Assets								
Investments:								
Cash and cash equivalents	\$	83,527	\$	_	\$	_	\$	83,527
Domestic equities		35,640		_		_		35,640
International equities		20,508		_		_		20,508
Fixed-income securities		_		15,385		_		15,385
U.S. government securities		_		8,339		_		8,339
Mutual funds and exchange-traded funds:								
Domestic equity funds		31,225		_		_		31,225
International equity funds		58,352		_		_		58,352
Fixed-income funds		74,266		_		_		74,266
Risk parity, blended, and other funds		31,083		_		_		31,083
Other		320		_		_		320
	\$	334,921	\$	23,724	\$	_	•	358,645
Investments measured at net asset value or equivalent:							-	
Fixed-income funds								242,327
Hedge funds								89,692
Private equity, real estate, and other								
funds								125,908
Total assets at fair value							\$	816,572

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The value of the plan assets measured at fair value on a recurring basis was determined using the valuation inputs described in Note 6 and categorized at June 30, 2019, as follows (in thousands):

	Level 1		Level 2		Level 3	Total
Assets						
Investments:						
Cash and cash equivalents	\$	112,672	\$ _	\$		\$ 112,672
Domestic equities		49,676	_		_	49,676
International equities		24,261	_		_	24,261
Fixed-income securities		_	13,724		_	13,724
U.S. government securities		_	8,242		_	8,242
Mutual funds and exchange-traded funds:						
Domestic equity funds		38,849	_		_	38,849
International equity funds		52,935	_		_	52,935
Fixed-income funds		68,542	_		_	68,542
Risk parity, blended, and other funds		21,804	_		_	21,804
Other		503	_		_	503
	\$	369,242	\$ 21,966	\$	_	391,208
Investments measured at net asset value or equivalent:						
Fixed-income funds						205,363
Hedge funds						107,920
Private equity, real estate, and other						•
funds						154,143
Total assets at fair value						\$ 858,634

The Cash Balance Plan has \$72,198,000 of funding commitments to purchase private equity, real estate, and other funds as of June 30, 2020.

TMF Plan

The method for establishing asset mix targets for the TMF Plan is consistent with that described above for the Cash Balance Plan.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The target asset mix is as follows as of June 30:

	2020	2019
Equity securities	33%	33%
Alternative investments	30	30
Fixed-income securities	35	35
Cash and cash equivalents	2	2
	100%	100%

The value of the plan assets measured at fair value on a recurring basis was determined using the valuation inputs described in Note 6 and categorized at June 30, 2020, as follows (in thousands):

	Level 1	Level 2	Level 3	Total
Assets				
Investments:				
Cash and cash equivalents	\$ 20,966	\$ -	\$ -	\$ 20,966
Domestic equities	4,460	_	_	4,460
International equities	551	_	_	551
Fixed-income securities	_	12,701	_	12,701
U.S. government securities	_	8,860	_	8,860
Mutual funds and exchange-				
traded funds:				
Domestic equity funds	21,177	_	_	21,177
International equity				
funds	10,183	_	_	10,183
Fixed-income funds	32,367	_	_	32,367
Risk parity, blended, and				
other funds	3,921	_	_	3,921
	\$ 93,625	\$ 21,561	\$ -	115,186
Investments measured at net				
asset value or equivalent:				
Fixed-income funds				18,180
Hedge funds				17,811
Total assets at fair value				\$ 151,177

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

The value of the plan assets measured at fair value on a recurring basis was determined using the valuation inputs described in Note 6 and categorized at June 30, 2019, as follows (in thousands):

	Level 1	Level 2	Level 3	Total
Assets				
Investments:				
Cash and cash equivalents	\$ 28,078	\$ _	\$ - \$	28,078
Domestic equities	4,059	_	_	4,059
International equities	549	_	_	549
Fixed-income securities	_	11,230	_	11,230
U.S. government securities	_	8,954	_	8,954
Mutual funds and exchange-				
traded funds:				
Domestic equity funds	19,698	_	_	19,698
International equity				
funds	10,693	_	_	10,693
Fixed-income funds	29,967	_	_	29,967
Risk parity, blended, and				
other funds	4,143	_	_	4,143
	\$ 97,187	\$ 20,184	\$ _	117,371
Investments measured at net				
asset value or equivalent:				
Fixed-income funds				14,534
Hedge funds				14,992
Total assets at fair value			\$	146,897

Contributions

In fiscal year 2021, CHRISTUS expects to contribute \$14,000,000 to the Defined Benefit Plans based on asset values for the plan year beginning January 1, 2019.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

Benefit Payments

The following benefit payments, which reflect expected future service and expected benefit payments for services previously rendered, are expected to be paid as follows (in thousands):

	Cash	TMF
	Balance Plan	<u>Plan</u>
2021	\$ 55,517	\$ 7,836
2022	54,770	8,147
2023	53,914	8,418
2024	53,715	8,683
2025	53,039	8,920
Years 2026–30	253,465	47,351

Defined Contribution Plans

The System has a defined contribution plan (the Matched Savings Plan) covering eligible CHRISTUS employees. Annual employee contributions are limited to 50% of compensation, up to Internal Revenue Service dollar limits. In fiscal 2019, the System matched 50% of employee contributions, not to exceed 6% of annual compensation, and employer contributions vest to the employee over a five-year period. In connection with the decision to freeze the Cash Balance Plan, effective July 1, 2019, the Matched Savings Plan was amended to increase the System's match from 50% to 67% of employee contributions, not to exceed 6% of annual compensation. Additionally, the amendment changed the vesting schedule to a three-year cliff vesting rather than 20% vesting each year over a five-year period. For the fiscal years ended June 30, 2020 and 2019, expenses attributable to the Matched Savings Plan amounted to \$30,475,000 and \$20,573,000, respectively.

Other Defined Benefit and Defined Contribution Plans

In addition to the CHRISTUS Cash Balance Plan and the TMF Plan, CHRISTUS also participates in various defined benefit plans for executives that have been frozen or curtailed. The net benefit credit and net benefit obligation under these plans was not material to the consolidated financial statements for the fiscal years ended June 30, 2020 or 2019. These plans are unfunded.

Notes to Consolidated Financial Statements (continued)

12. Employee Benefit Plans (continued)

In addition to the Matched Savings Plan, CHRISTUS also participates in other defined contribution plans that are not material to the consolidated financial statements for the fiscal years ended June 30, 2020 or 2019.

13. Self-Funded Liabilities

The System self-funds and self-insures for primary professional and general liability, workers' compensation and Texas occupational injury, directors' and officers' liability, employment practices liability, property, and employee medical benefits. A wholly owned, captive insurance company, Emerald Assurance Cayman Ltd. (Emerald), is used to fund primary professional and general liability, property, directors' and officers' liability, and employment practices liability. Policies written provide coverage for professional liability with primary limits of \$10,000,000 per claim with no aggregate for the fiscal years 2020 and 2019. For general liability, policies written provide coverage with primary limits in the amount of \$2,000,000 per claim for fiscal years 2020 and 2019. Additionally, the System internally sets aside funds for workers' compensation, Texas occupational injury program, and employee medical benefits based on actuarial analyses.

Prior to fiscal year 2018, TMF, which was acquired by the System on May 1, 2016, maintained a separate insurance program covering all coverages, except directors' and officers' liability, employment practices liability, property insurance, and occupational injury (workers' compensation program). TMF's directors' and officers' liability, employment practices liability, and property insurance coverages were merged into the System program on May 1, 2016. TMF's occupational injury (workers' compensation program) was merged with the CHRISTUS program on January 1, 2017. TMF was self-insured for the first \$3,000,000 of each medical malpractice claim and funded a healthcare liability trust for payment of malpractice losses and expenses. The estimated self-funded losses include expected claim payments, including settlement costs for reported claims and an actuarial determination of expected losses related to claims that have been incurred but not reported. TMF was also a Texas Certified Self-Insurer for workers' compensation and sets aside funds for workers' compensation and employee medical benefits for claims occurring up until January 1, 2017. Commercial insurance policies cover other risk exposures, including ambulance and auto liability; aviation liability; cyber liability; and excess professional, general, and workers' compensation liability. Effective July 1, 2017, any claims for all TMF coverages except professional liability for physicians employed by CHRISTUS Trinity Clinic were covered through the System risk finance program. The CHRISTUS Trinity Clinic employed physicians continue to be covered under the TMF healthcare liability trust.

Notes to Consolidated Financial Statements (continued)

13. Self-Funded Liabilities (continued)

The assets of the captive insurance company, internally designated funds, and the estimated liability for losses are reported in the consolidated balance sheets. Investment income from the assets and the provision for estimated self-funded losses and administrative costs are reported in the accompanying consolidated statements of operations and changes in net assets. The estimated self-funded losses include expected claim payments, including settlement costs for reported claims and an actuarial determination of expected losses related to claims that have been incurred but not reported.

Emerald was incorporated in the Cayman Islands on June 27, 2003, and operates subject to the provisions of the Companies Law (2003 Revision) of the Cayman Islands. Emerald was granted an Unrestricted Class "B" Insurer's license on June 30, 2003 (reclassified to a Class B(i) license on September 21, 2015), which it holds subject to the provisions of the Insurance Law (2003 Revision) of the Cayman Islands. As a Cayman Islands company, Emerald is exempt from local income, profits, and capital gains taxes until July 29, 2023. No such taxes are currently levied in the Cayman Islands.

14. Commitments and Contingencies

Capital Commitments

The System has committed to fund \$700,000,000 in capital expenditures related to the acquisition of Trinity Mother Frances Health System in May 2016. The commitment is to be funded over a period of up to seven years from funds generated by the operations of Trinity Mother Frances Health System and other resources. The System reports the expenditures as of April 30 of each year to Covenant Corporation, an external organization established at the time of the purchase. As of April 30, 2020, the System had expended \$460,651,000 toward the commitment.

Other Contingencies

From time to time, the System is subject to litigation in the ordinary course of operations. Management is not aware of any pending or threatened litigation that would have a material effect on the System's consolidated financial statements.

Healthcare is a highly regulated industry. The System has a compliance program and various internal policies and procedures that are designed to ensure compliance with applicable federal, state, and local laws and regulations and reduce potential exposure to fines, penalties, repayment

Notes to Consolidated Financial Statements (continued)

14. Commitments and Contingencies (continued)

obligations, and other sanctions for violations of such laws and regulations. As a result of the System's compliance, internal audit, and other operational activities, from time to time the System identifies instances in which it has a repayment or self-disclosure obligation. In addition, the System may incur repayment obligations or be subject to penalties as a result of audits and investigations by governmental agencies and contractors or commercial payors.

Because the government's present regulatory and enforcement efforts are widespread across the healthcare industry and may vary from region to region, the impact of such activities on the System is difficult to predict with certainty. The dynamic regulatory environment, political climate, and effectiveness of the System's compliance efforts are all factors that may affect the resolution of regulatory, enforcement, and payor issues involving System entities. The System has implemented, and continually works to enhance, various policies and procedures to ensure compliance with applicable legal requirements. However, there can be no assurance that the System's compliance program or other measures will be able to reduce or eliminate all potential exposure for alleged or actual noncompliance with applicable laws and regulations or commercial payor requirements.

15. Functional Expenses

The System's primary activities involve providing general healthcare services to its patients. Expenses related to providing these services at June 30 are as follows (in thousands):

					2020)	
		Healthcare Services		Physician Services	General and Administrative		Total
Employee compensation and							
benefits	\$	1,885,891	\$	490,063	\$	221,957	\$ 2,597,911
Services and other		1,511,726		63,160		168,079	1,742,965
Supplies		920,409		19,224		13,922	953,555
Depreciation and amortization		217,913		7,550		19,710	245,173
Interest		10,369		1,118		48,092	59,579
Total expenses	\$	4,546,308	\$	581,115	\$	471,760	\$ 5,599,183

Notes to Consolidated Financial Statements (continued)

15. Functional Expenses (continued)

	2019						
	Ŧ	Healthcare Services	-	Physician Services		General and dministrative	Total
Employee compensation and							
benefits	\$	1,656,833	\$	455,474	\$	398,342	\$ 2,510,649
Services and other		1,200,167		84,643		403,106	1,687,916
Supplies		919,804		18,266		13,747	951,817
Depreciation and amortization		179,130		4,946		46,875	230,951
Interest		16,061		848		36,321	53,230
Total expenses	\$	3,971,995	\$	564,177	\$	898,391	\$ 5,434,563

16. Liquidity

Financial assets available for general expenditure within one year of the balance sheet date consist of the following as of June 30 (in thousands):

	 2020	2019
Cash and cash equivalents	\$ 1,271,062	\$ 578,621
Short-term investments and equity in managed funds	882,313	755,192
Patient accounts receivable	 500,091	534,190
Total	\$ 2,653,466	\$ 1,868,003

CHRISTUS has the ability to structure its financial assets to be available as its general expenditures and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. CHRISTUS also maintains a \$150,000,000 line of credit with Sumitomo Mitsui Banking Corporation – New York Operations and a \$100,000,000 line of credit with JPMorgan Chase Bank, National Association as discussed in Note 10. As of June 30, 2020, \$217,000,000 remained available under those lines of credit.

Notes to Consolidated Financial Statements (continued)

17. Net Assets With Donor Restrictions

Net assets with donor restrictions at June 30 are restricted for the following purposes (in thousands):

	2020	2019
Healthcare services	\$ 110,859 \$	115,278
Purchase of equipment/capital improvement	47,330	39,185
Indigent care	616	300
Health education	3,454	2,813
Community outreach	14,254	12,762
Investments to be held in perpetuity, the income from which is expendable to support healthcare services		
(reported as operating income)	8,964	8,488
Endowment requiring income to be added to original gift	3,307	1,046
Other	 16,585	26,494
Total	\$ 205,369 \$	206,366

Notes to Consolidated Financial Statements (continued)

18. Changes in Consolidated Net Assets Without Donor Restrictions

Changes in consolidated net assets without donor restrictions that are attributable to the System and the noncontrolling interests in subsidiaries are as follows (in thousands):

	C	Controlling Interest	No	oncontrolling Interests	į	Total
Balance, July 1, 2018	\$	2,963,671	\$	238,122	\$	3,201,793
Revenues in excess of expenses		90,522		35,923		126,445
Distributions		_		(8,044)		(8,044)
Net assets acquired from sale of						
noncontrolling interests		2,967		57,686		60,653
Change in pension liabilities		(61,183)		_		(61,183)
Other activities		11,115		9,117		20,232
Balance, June 30, 2019	***************************************	3,007,092		332,804		3,339,896
Revenues in excess of expenses		92,643		36,055		128,698
Distributions		_		(8,040)		(8,040)
Net assets acquired from acquisition				, - ,		
and sale of noncontrolling interests		(460)		2,642		2,182
Change in pension liabilities		(54,717)		_		(54,717)
Cumulative effect of change in		, ,				
accounting principle		7,129		_		7,129
Other activities		(31,919)		2,566		(29,353)
Balance, June 30, 2020	\$	3,019,768	\$	366,027	\$	3,385,795

19. International Operations

CHRISTUS Muguerza

At June 30, 2020, the System owns a 90.5% interest in CHRISTUS Muguerza, S.A. de C.V. (CHRISTUS Muguerza), headquartered in Monterrey, Mexico. CHRISTUS Muguerza is a private healthcare system and is subject to taxes in accordance with the regulations of the Republic of Mexico. The financial statements of CHRISTUS Muguerza are presented in accordance with U.S. GAAP and are included in CHRISTUS' consolidated financial statements. CHRISTUS Muguerza has net assets of \$146,421,000 and \$158,199,000 at June 30, 2020 and 2019, respectively.

Notes to Consolidated Financial Statements (continued)

19. International Operations (continued)

In November 2012, the System and certain noncontrolling interest holders entered into a revised shareholders' agreement whereby the noncontrolling interest holders of CHRISTUS Muguerza have a series of put options through December 31, 2028. These options will require the System to acquire shares, subject to an annual cap of either \$3,500,000 or \$2,000,000, depending on the year, at a formula price as defined. At June 30, 2020 and 2019, the System had \$6,216,000 and \$6,209,000, respectively, recorded as net assets without donor restrictions attributable to noncontrolling interest to reflect such obligation to the noncontrolling interest holders in connection with the agreement.

During 2020, the System purchased 5,429,778 shares from the noncontrolling shareholders in accordance with the agreement for cash consideration of \$5,816,000, which increased its ownership interest in CHRISTUS Muguerza from 87.3% to 90.5%. During 2019, the System increased its ownership interest in CHRISTUS Muguerza from 86.6% to 87.3% for cash consideration of \$1,959,000.

Chile Operations

CHRISTUS' joint venture with PUC, CHRISTUS Salud, owns and operates an integrated health network consisting of an acute care hospital, health clinics, urgent care centers, family health centers, and lab and radiology services in Santiago, Chile. In addition to the operations of the joint venture, CHRISTUS manages the operations of PUC's health network. PUC is owned by the Catholic Church and operates one of the largest health systems in Chile for medical care and teaching.

Concurrently with the formation of the joint venture, CHRISTUS and PUC executed management and license agreements, under which CHRISTUS provides management services and licenses its trade name and certain other intellectual property to PUC's primary hospital. CHRISTUS and CHRISTUS Salud also entered into management and license agreements under which CHRISTUS provides management services and licenses its trade name and certain other intellectual property to all of the joint venture operations. The initial term of these agreements is 25 years. CHRISTUS recorded other revenue related to the management and license fee agreements of \$14,488,000 and \$10,660,000 during the fiscal years ended June 30, 2020 and 2019, respectively. CHRISTUS is committed to make additional capital contributions to CHRISTUS Salud at various times over the next five years. Specific amounts of additional capital contributions may vary but are expected to be no less than \$51,000,000. The investment in CHRISTUS Salud is treated as an equity method investment. Discussion of the investment and earnings is in Note 9.

Notes to Consolidated Financial Statements (continued)

19. International Operations (continued)

During fiscal years 2015 through 2018, Amatista Financing Company, Ltd., a wholly owned subsidiary of CHRISTUS, executed various loan agreements with PUC (PUC Loans), a related party, and as of June 30, 2020, has loaned PUC a total of \$70,000,000 under the terms of those agreements. In July 2018, the first \$30,000,000 in notes, together with accrued interest, were repaid. The remaining notes carry an interest rate of 3.17% per annum. Of the remaining notes, \$20,000,000 matures in August 2021, and \$20,000,000 matures in March 2022. At June 30, 2020 and 2019, accrued interest related to the PUC Loans was \$321,000 and \$309,000, respectively. At June 30, 2020, CHRISTUS had an allowance against these notes for the full \$40,000,000 that remains outstanding. The PUC Loans and related allowance are reported within other noncurrent assets in the accompanying consolidated balance sheets.

Colombia Operations

Effective June 14, 2016, CHRISTUS Health Colombia S.A.S. and CHRISTUS Rendimiento, wholly owned subsidiaries of CHRISTUS, signed definitive agreements with Coomeva in Colombia. In September 2016, CHRISTUS closed on various transactions outlined in the definitive agreements, resulting in CHRISTUS obtaining a noncontrolling ownership interest in Sinergia and MP. Sinergia is a healthcare provider that owns and operates hospitals, outpatient clinics, and home care services. MP owns and operates a private insurance company and ambulance services. Discussion of the investments and related earnings on those investments is in Note 9.

In addition to these investments, in September 2016 CHRISTUS executed a loan with Coomeva EPS, an affiliate of Coomeva, for \$2,578,000. Coomeva EPS is a health insurance company that contracts with the Colombian government. The loan was converted into equity securities of Coomeva EPS and carries a put option that CHRISTUS can exercise upon the occurrence of certain triggering events.

As part of the definitive agreements, CHRISTUS also entered into management agreements with Coomeva affiliates and earns a management fee for services provided under those agreements. During fiscal year 2019, CHRISTUS has applied a constraint against these management fees and revenue will be recognized once uncertainty regarding collectibility has been resolved. During the fiscal years ended June 30, 2020 and 2019, CHRISTUS recorded \$4,266,000 and \$725,000, respectively, in management fee revenue under these agreements, which is classified as other revenue in the accompanying consolidated financial statements.

Notes to Consolidated Financial Statements (continued)

20. Significant Events

Business Combinations

Central Texas Medical Center

Effective April 1, 2020, CHRISTUS closed on a transaction with Adventist Health System, in which CHRISTUS paid approximately \$32,500,000 plus working capital and other adjustments to acquire Central Texas Medical Center (CTMC), together with certain related businesses, including physician clinic operations. CTMC is a full-service acute care hospital located in San Marcos, Texas. The transaction was accounted for using the acquisition method of accounting.

The fair values assigned are preliminary and subject to change as valuation activities are finalized and are summarized as follows (in thousands):

Consideration transferred	\$ 33,353
Fair values of assets acquired and liabilities assumed:	
Current assets	3,495
Property and equipment, net	29,278
Other noncurrent assets	8,909
Current liabilities	(1,751)
Long-term liabilities	(6,578)
Total fair values of assets acquired and liabilities assumed	\$ 33,353

The fair value of assets acquired less liabilities assumed was equal to the purchase price; as such, no goodwill was recognized.

For the period from April 1, 2020 through June 30, 2020, total operating revenue and revenues in excess (deficit) of expenses attributable to CTMC were \$17,816,000 and \$(4,712,000), respectively.

Notes to Consolidated Financial Statements (continued)

20. Significant Events (continued)

Sale of Noncontrolling Interest

Effective September 1, 2018, CHRISTUS and Ochsner Clinic Foundation (Ochsner) executed a membership interest purchase agreement whereby Ochsner acquired a 40% noncontrolling membership interest in CHRISTUS Health Southwest Louisiana (SWLA) for \$59,329,000, subject to certain working capital and other adjustments. The purchase price was paid with \$35,000,000 in cash and the remaining amount in the form of a five-year promissory note. CHRISTUS and Ochsner also executed a Clinic Services Agreement under which Ochsner will manage SWLA's physician clinics and physician-employee medical practices. In connection with this transaction, SWLA was removed from the CHRISTUS Health Obligated Group.

COVID-19

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Patient volumes and the related revenue for most services were significantly impacted beginning in mid-March 2020 as various policies were implemented by federal, state, and local governments in response to the COVID-19 pandemic, including stay-at-home orders, business closures, social distancing, and suspension of elective and nonemergent procedures. In early May, certain of these policies, such as suspension of elective and nonemergent procedures, were lifted and the System experienced gradual improvement in volumes and related revenue. In response to this crisis, the federal government instituted various relief programs that made funds available to healthcare facilities in order to preserve cash flows. CHRISTUS received funding from various relief programs, the most significant being the Medicare Advance Payment program and the CARES Act (see Note 4).

21. Subsequent Events

The System evaluated events and transactions occurring subsequent to June 30, 2020 through September 24, 2020, the date of issuance of the accompanying consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. However, the following events occurred that warrant disclosure.

Term Loan

On July 15, 2020, the System entered into a term loan agreement with JPMorgan Chase Bank, National Association for \$100,000,000. The term loan carries an interest rate of 2.13% and matures on July 1, 2027. The funds related to this term loan were received on August 14, 2020. These funds

Notes to Consolidated Financial Statements (continued)

21. Subsequent Events (continued)

were used, in part, to repay the \$33,000,000 outstanding balance on the System's \$150,000,000 line of credit facility with Sumitomo Mitsui Banking Corporation on September 3, 2020.

Hurricane Laura

In August 2020, various hospitals and other physical structures in the CHRISTUS Southeast Texas and CHRISTUS Louisiana ministries sustained damage from Hurricane Laura resulting in property damage and business interruption. CHRISTUS is in the process of estimating total damages sustained as a result of this event. CHRISTUS maintains property and business interruption insurance coverage through independent property and casualty companies. Additionally, CHRISTUS has self-insured property and casualty losses at the individual facility level through a wholly owned captive insurance company, Emerald Assurance.

2005-3516145 73

Supplementary Information



Ernst & Young LLP One Victory Park Suite 2000 2323 Victory Avenue Dallas, TX 75219 Tel: +1 214 969 8000 Fax: +1 214 969 8587 ey.com

Report of Independent Auditors on Supplementary Information

The Board of Directors CHRISTUS Health

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying community benefit information is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management. The information has not been subjected to the auditing procedures applied in our audits of the consolidated financial statements and, accordingly, we express no opinion on it.

Ernst + Young LLP

September 24, 2020

Community Benefit (Unaudited)

CHRISTUS Health (CHRISTUS or the System) complies with the Catholic Health Association's (CHA) A Guide for Planning and Reporting Community Benefits (2008) and the state of Texas reporting requirements. CHA guidelines have adopted the instructions for IRS Form 990, Schedule H, Hospitals.

Following is a summary of the System's quantifiable costs of community benefits provided for the fiscal years ended June 30 (in thousands):

	2020		2019
	 (Unaudited)		
Programs and services for the poor and underserved:			
Charity care at unpaid cost	\$ 276,137	\$	290,531
Unpaid cost of Medicaid and other public programs	64,477		71,909
Community services for the poor and underserved	54,324		54,979
Total programs and services for the poor and underserved	394,938		417,419
Community services for the broader community:			
Education and research	9,081		9,354
Other community services	19,967		21,416
Total community services for the broader community	29,048		30,770
Total community benefits	\$ 423,986	\$	448,189

The totals are calculated following CHA guidelines and adhere to the IRS Form 990, Schedule H methodology. CHRISTUS has multiple reporting requirements of charity care and community benefit, which vary based on the definitional and timing requirements of each requesting organization. For comparability, the unpaid cost of Medicaid and other public programs total for fiscal year 2019 has been updated to reflect the change in methodology effective for fiscal year 2020 reporting.

In addition to the community benefits reported above, the state of Texas requires that the unpaid costs of Medicare and other government-sponsored programs be reported. For the fiscal years ended June 30, 2020 and 2019, the unpaid costs of these programs were \$349,134,000 and \$294,288,000, respectively. The unpaid costs of the Medicare program represent the cost of providing services to primarily elderly beneficiaries of the Medicare program, in excess of governmental and managed care contract payments. The unpaid costs of other government-sponsored programs represent the cost for providing healthcare services to the beneficiaries of the Department of Defense civilian care, included as per the state of Texas guidelines.

CHRISTUS provides community benefits in Mexico to the poor and underserved, as well as for the broader community. For the fiscal year ended June 30, 2020, the quantifiable costs of community benefits provided in Mexico were \$6,710,588.

2005-3516145 75

Supplementary Information – Federal and State Awards

Schedule of Compensation Information

Years Ended June 30, 2020 and 2019

Chief Executive Officer: Ernie Sadau

None of the Chief Executive Officer's compensation was paid from public funds received by CHRISTUS Health.

2104-3758386 76

Schedule of Expenditures of Federal and State Awards

Year Ended June 30, 2020

Federal Grantor/State Grantor/ Pass-Through Grantor-Program Title	Assistance Listing Number	Pass-Through Entity Identifying Number'State Contract Number	Research and Development Cluster	Other Federal/State Expenditures	Total Federal/State Expenditures	Amounts Provided to Subrecipients	Location
Federal Awards							
U.S. Department of Agriculture							
Indirect Awards							
Pass-through from the Texas Department of State Health Services:							
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10 557	2017-049848-001-FY19	\$ -	\$ 276,545	\$ 276,545	\$ -	CHRISTUS Santa Rosa Health System
WIC Special Supplemental Nutrition Program for Women, Infants, and Children	10 557	2017-049848-001-FY20		738,165	738,165	98.463	CHRISTUS Santa Rosa Health System
Total WIC Special Supplemental Nutrition Program for Women, Infants, and Children			_	1,014,710	1,014,710	98,463	_
Pass-through from the Texas Department of State Health Services:							
Snæp Cluster							
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program	10.561	2017-049848-001-FY20		621	621	_	CHRISTUS Santa Rosa Health System
Total U.S. Department of Agriculture			=	1,015,331	1,015,331	98,463	
U.S. Department of Justice							
Indirect Awards							
Pass-through from the New Mexico Crime Victims Reparation Commission:							
Crime Victim Assistance	16 575	2019-VA-714	-	15,706	15,706	_	CHRISTUS St. Vincent Regional Medical Center
Crime Victim Assistance	16 575	2020-VA-822	-	15,209	15,209	_	CHRISTUS St. Vincent Regional Medical Center
Pass-through from the Texas Office of the Governor:							
Crime Victim Assistance	16.575	3785801	-	24,075	24,075	_	CHRISTUS Health Southeast Texas
Crime Victim Assistance	16.575	3282202	-	41,447	41,447	-	CHRISTUS Santa Rosa Health System
Crime Victum Assistance	16.575	3282202	-	134,466	134,466	-	CHRISTUS Santa Rosa Health System
Total Crime Victim Assistance			_	230,903	230,903	_	-
Pass-through from the Texas Office of the Governor:			*				-
Violence Against Women Formula Grants	16.588	3789401	-	12,558	12,558	-	CHRISTUS Health Southeast Texas
Total U.S. Department of Justice			_	243,461	243,461	_	-
U.S. Department of Health and Human Services							
Direct Awards							
COVID-19 Testing for the Uninsured	93.461		_	2,474,293	2,474,293	_	CHRISTUS Health System
Accountable Health Communities	93 650	1P1CMS331603-03-01	-	400,715	400,715	_	CHRISTUS Santa Rosa Health System
Accountable Health Communities	93 650	1P1CMS331603-04-00	_	85,424	85,424	_	CHRISTUS Santa Rosa Health System
Total Accountable Health Communities				486.139	486,139	_	<u>. </u>
Direct Awards Total			_	2,960,432	2,960,432	_	_
Indirect Awards							-
mattect Awaras Pass-through from Baylor College of Medicine:							
Research on Healthcare Costs, Quality and Outcomes	93.226	IR18HS026169-01	37,477	_	37,477	_	CHRISTUS Santa Rosa Health System
Research on Healthcare Costs, Quality and Outcomes Research on Healthcare Costs, Quality and Outcomes	93.226	5R18HS026169-01	33,614	_	33,614	_	CHRISTUS Santa Rosa Health System CHRISTUS Santa Rosa Health System
Total Research on Healthcare Costs, Quality and Outcomes	93 220	JK10H30Z0109-02	71.091		71.091		CIRCLE I CO SHINK RUSH FICHINI SYSTEM
Pass-through from the Texas Department of State Health Services:			/1,091	_	71,091	_	-
Centers for Disease Control and Prevention Investigations and Technical Assistance	93.283	529-17-0023-00032A	-	14,184	14,184	-	CHRISTUS Health Ark-La-Tex

Schedule of Expenditures of Federal and State Awards (continued)

Federal Grantor/State Grantor/ Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity Identifying Number/State Contract Number	Research and Development Cluster	Other Federal/State Expenditures	Total Federal/State Expenditures	Amounts Provided to Subrecipients	Location
Federal Awards (continued)							
Pass-through from the New Mexaco Department of Health:							
Public Health Emergency Response: Cooperative Agreement for Emergency Response							
Public Health Crisis Response	93.354	20-665-0300-22798	\$ -	\$ 100,000	\$ 100,000	s –	CHRISTUS St. Vincent Regional Medical Center
Pass-through from Oregon Health and Science University:							
Cancer Treatment Research	93.395	2U10CA180888-06	69,444	_	69,444	-	CHRISTUS Santa Rosa Health System
Pass-through from the Louisiana Hospital Association:							
National Bioterrorism Hospital Preparedness Program	93 889	72-0408 98 4	=	95,755	95,755	-	CHRISTUS Health Central Louisiana
Pass-through from the Piney Woods Regional Advisory Council Trauma Service Area G:							
National Bioterrorism Hospital Preparedness Program	93.889	75-2603041	_	2.536	2,536	_	CHRISTUS Trusty Mother Frances Health System
Total National Bioterrorism Hospital Preparedness Program			_	98,291	98,291		
Pass-through from LSU Health Science Center New Orleans							
Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations	93.898	PH-19-111-007-A2	65,449	_	65,449	-	CHRISTUS Health Central Louisiana
Pass-through from the Texas Department of State Health Services:				***			
Maternal and Child Health Services Block Grant to the States	93 994	HHS000043600005	=	301,212	301,212	-	CHRISTUS Santa Rosa Health System
Pass-through from the University of Michigan:			****				
National Institutes of Health - Various Studies	93.RD	SUBK00005107	11,000	2 121 112	11,000	_	CHRISTUS Spohn Health System
Total U.S. Department of Health and Human Services			216,984	3,474,119	3,691,103	-	
U.S. Department of Homeland Security Inducet Awards: Pass-through from the Texas Department of Public Safety:							
Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97 036	4332DRTXP0000001	-	1,349,908	1,349,908	-	CHRISTUS Health
Total U.S. Department of Homeland Security			_	1,349,908	1,349.908	-	-
Total Expenditures of Federal Awards			\$ 216,984	\$ 6,082,819	\$ 6,299,803	\$ 98,463	- - -
State Awards							
Texas							
Graduate Medical Education Program:							
Direct Awards (Texas Higher Education Coordinating Board):							
Family Practice Residency Program							
Family Practice Residency Program Operational Grant		THECB 22498	s –	\$ 159 _. 015	\$ 159.015	\$ -	CHRISTUS Santa Rosa Health System
Family Practice Residency							
Program - Primary Care		THECB 22471	-	70,673	70,673	70,673	CHRISTUS Health Ark-La-Tex
Family Practice Residency							
Program Operational Grant		THECB 22459	-	212,019	212,019	-	CHRISTUS Spohn Health System
Family Medicine Residents Rural Rotation		THECB Various Physicians	_	5,000	5,000	_	CHRISTUS Spohn Health System
Total Family Practice Residency Program			_	446.707	446,707	70,673	i e

78

Schedule of Expenditures of Federal and State Awards (continued)

Federal Grautor/State Grantor/ Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity Identifying Number/State Contract Number	•	Other Federal/State Expenditures	Total Federal/State Expenditures	Amounts Provided to Subrecipients	Location
			CILIXI	2.2/CIMINIDES	Lipianita	оцина	200,1101
State Awards (continued)							
Graduate Medical Education Expansion Program: Graduate Medical Education							
Expansion Program – Pediatrics		THECB 19700	s – s	2,700.000	S 2,700,000	s 2.700.000	CHRISTUS Santa Rosa Health System
Expansion Program – Pedrames Graduate Medical Education		IRECD 19700	s – s	2,760,000	3 2,700,000	\$ 2.700,000	CARISTUS Santa Roya rieann System
Expansion Program – Family Medicine		THECB 19703		450.000	450,000		CHRISTUS Santa Rosa Health System
Graduate Medicai Education		THEX.B 17703		430,000	430,000		CIRLSTOS Santa Rosa Heann System
Expansion Program - Emergency Medicine		THECB 19702	_	450,000	450,000	_	CHRISTUS Spohn Health System
Total Graduate Medical Expansion Education Program		111120117702		3,600,000	3,600,000	2,700,000	emusi os spom irami system
Total Graduate Medical Education Program				4,046,707	4.046.707	2,770,673	•
COM GROUND MEDICAL LOSEAN				1,010,707	1,010.201	2.214,015	
Direct Award (Texas Department of State Health Services)							
Texas Breast and Cervical Cancer Program		529-17-0023-00032A	-	4,180	4,180	-	CHRISTUS Health Ark-La-Tex
birect Award (Office of the Governor, Public Safety Office)							
Sexual Assault Forensic Exam (SAFE) - Ready		3942801	-	832	832	=	CHRISTUS Health Southeast Texas
Direct Award (Office of the Governor)							
Child Sex Trafficking-Prevention, Investigation and Prosecution		3800401	-	44.606	44 <u>.</u> 60 6	-	CHRISTUS Health Southeast Texas
ndirect Award (Cancer Prevention and Research Institute of Texas)							
ass-through from the University of Texas Health Science Center at Houston:							
Adolescent Vaccination Program (AVP)		0013880B	78,754	=	7 8 ,75 4	-	CHRISTUS Santa Rosa Health System
otal Expenditures of State Awards - Texas			78,754	4,096,325	4,175,079	2,770,673	•
ыканзаз							
Direct Awards (Arkansas Department of Health):							
Arkansas Department of Health Trauma Designation Sustaining Grant		4600044415	-	135,000	135,000	_	CHRISTUS Health Ark-La-Tex
Arkansas Department of Health Advanced Stroke and Life Support Grant		4600042202	_	2,250	2,250	_	CHRISTUS Health Ark-La-Tex
otal Expenditures of State Awards - Arkansas			_	137,250	137,250	-	
ouisiana							
Direct Awards (Louisiana Department of Health)							
Louissana Department of Health Cooperative Endeavor		2000411954	=	6,753	6,753	=	CHRISTUS Health Central Louisiana
otal Expenditures of State Awards - Louisiana			_	6,753	6,753	_	•
otal Expenditures of State Awards			\$ 78,754 \$	4.240,328		\$ 2,770,673	
otal Expenditures of Federal and State Awards			\$ 295,738 \$	10,323,147	\$ 10,618,885	\$ 2,869,136	•

See accompanying notes to schedule of expenditures of federal and state awards.

Notes to Schedule of Expenditures of Federal and State Awards

June 30, 2020

1. Basis of Presentation

The accompanying schedule of expenditures of federal and state awards (the Schedule) includes the federal and state award activity of CHRISTUS Health under programs of the federal and state governments for the year ended June 30, 2020. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and the State of Texas Uniform Grant Management Standards (UGMS). Because the Schedule presents only a selected portion of the operations of CHRISTUS Health, it is not intended to and does not present the financial position, results of operations, changes in net assets, or cash flows of CHRISTUS Health.

2. Summary of Significant Accounting Policies

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following, as applicable, the cost principles contained in the Uniform Guidance, 45 CFR, PART 75 APPENDIX IX, *Principles for Determining Costs Applicable to Research and Development Under Grants and Contracts With Hospitals*, and the State of Texas UGMS, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

CHRISTUS Health has negotiated multiple indirect cost rates for consolidated entities that have been eligible to negotiate a federal indirect cost rate with the Department of Health and Human Services (DHHS). However, not all awards presented in the Schedule include indirect expenses. Allowable indirect costs for each award are determined by the related terms and conditions developed by the awarding agency for each program. CHRISTUS Health has not elected to use the 10% de minimis indirect cost rate allowed under Uniform Guidance.

3. Nature of Activities

CHRISTUS Health receives various grants to cover costs of specified programs. Final determination of eligibility of costs will be made by the grantors. Should any costs be found ineligible, CHRISTUS Health will be responsible for reimbursing the grantors for these amounts.

Notes to Schedule of Expenditures of Federal and State Awards (continued)

3. Nature of Activities (continued)

Additionally, expenditures incurred for various programs may exceed the amounts awarded from the respective pass-through entity or agency. The amounts reported on the Schedule are limited to the award amounts. Amounts in excess of this amount are paid out of non-federal and non-state sources.

4. Disaster Grants – Public Assistance (Presidentially Declared Disasters)

For the Federal Emergency Management Agency (FEMA), Department of Homeland Security's (DHS) Disaster Grants – Public Assistance (Presidentially Declared disasters) (Assistance Listing Number 97.036), non-federal entities must record expenditures on the Schedule when (1) FEMA has approved the non-Federal entity's project worksheet (PW), and (2) the non-Federal entity has incurred the eligible expenditures. Federal awards expended in years subsequent to the fiscal year in which the PW is approved are to be recorded on the non-Federal entity's Schedule in those subsequent years.

In fiscal year 2020, CHRISTUS Health received approval from the Texas Department of Public Safety for seven PWs related to the reimbursement of eligible costs of \$1,349,908 incurred in previous fiscal years. These previous years' expenditures are included on the Schedule in the current year in accordance with guidance provided by DHS.

5. Donated Personal Protective Equipment

[unaudited] CHRISTUS Health received \$530,056 of donated personal protective equipment (PPE) purchased with federal assistance funds for the year ended June 30, 2020. PPE is valued based on fair market value at the time of receipt.



Ernst & Young LLP One Victory Park Suite 2000 2323 Victory Avenue Dallas, TX 75219 Tel: +1 214 969 8000 Fax: +1 214 969 8587 ev.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

The Board of Directors and Management CHRISTUS Health

We have audited, in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of CHRISTUS Health, which comprise the consolidated balance sheet as of June 30, 2020, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated September 24, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered CHRISTUS Health's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of CHRISTUS Health's internal control. Accordingly, we do not express an opinion on the effectiveness of CHRISTUS Health's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



Compliance and Other Matters

As part of obtaining reasonable assurance about whether CHRISTUS Health's consolidated financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

September 24, 2020



Ernst & Young LLP One Victory Park Suite 2000 2323 Victory Avenue Dallas, TX 75219 Tel: +1 214 969 8000 Fax: +1 214 969 8587 ey.com

Report of Independent Auditors on Compliance for Each Major Federal and State Program and Report on Internal Control Over Compliance Required by the Uniform Guidance and State of Texas Uniform Grant Management Standards

The Board of Directors and Management CHRISTUS Health

Report on Compliance for Each Major Federal and State Program

We have audited CHRISTUS Health's compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) Compliance Supplement that could have a direct and material effect on CHRISTUS Health's major federal program and the types of compliance requirements described in the State of Texas Uniform Grant Management Standards (UGMS) that could have a direct and material effect on CHRISTUS Health's major state program for the year ended June 30, 2020. CHRISTUS Health's major federal and state programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal and state statutes, regulations and the terms and conditions of its federal and state awards applicable to its federal and state programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of CHRISTUS Health's major federal and state programs based on our audit of the types of compliance requirements referred to above.

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance), and the State of Texas UGMS. Those standards, the Uniform Guidance and the State of Texas UGMS require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal or state program occurred. An audit includes examining, on a test basis, evidence about CHRISTUS Health's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.



We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal and state program. However, our audit does not provide a legal determination of CHRISTUS Health's compliance.

Opinion on Each Major Federal and State Program

In our opinion, CHRISTUS Health complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal and state programs for the year ended June 30, 2020.

Report on Internal Control Over Compliance

Management of CHRISTUS Health is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered CHRISTUS Health's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal and state program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal or state program and to test and report on internal control over compliance in accordance with the Uniform Guidance and State of Texas UGMS, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of CHRISTUS Health's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal or state program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal or state program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal or state program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and State of Texas UGMS. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

September 22, 2021

Schedule of Findings and Questioned Costs

Year Ended June 30, 2020

Section I – Summary of Auditor's Results

Financial Statements

Type of auditor's report issued on whether the financial statements audited were prepared in	TT	······ 1: E - 1
accordance with GAAP:	U	nmodified
Internal control over financial reporting: Material weakness(es) identified?	Yes	X No
Significant deficiency(ies) identified? Noncompliance material to financial statements noted?	Yes Yes	X None reported X No
Federal Awards		
Internal control over major federal programs: Material weakness(es) identified? Significant deficiency(ies) identified?	Yes Yes	X No None reported
Type of auditor's report issued on compliance for major federal programs:		Unmodified
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	Yes	X No
State Awards Internal control over major state programs: Material weakness(es) identified? Significant deficiency(ies) identified?	Yes Yes	X No None reported
Type of auditor's report issued on compliance for major state programs:	τ	Unmodified
Any audit findings disclosed that are required to be reported in accordance with Section .510(a) of Part IV of the State of Texas Uniform Grant Management Standards?	Yes	X No

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor's Results (continued)

Identification of major federal programs:

Assistance Listing Number(s)	Name of Federal Program or Cluster
93.461	COVID-19 Testing for the Uninsured
Dollar threshold used to distinguish between Type A and Type B federal programs:	\$750,000
Auditee qualified as low-risk auditee?	X No
Identification of major state programs:	
Assistance Listing Number(s)	Name of State Program or Cluster
N/A	Graduate Medical Education Program
Dollar threshold used to distinguish between Type A and Type B state programs:	\$300,000
Auditee qualified as low-risk auditee?	Yes No
Section II – Financial Statement Findings	
No findings were noted.	
Section III – Federal Award Findings and Ques	stioned Costs
No findings were noted.	
Section IV – State Award Findings and Question	oned Costs
No findings were noted.	

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2021 Ernst & Young LLP. All Rights Reserved.

ey.com



Summary Schedule of Prior Audit Findings

Year Ended June 30, 2020

No findings were noted in 2019 or 2018.